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   Peroxisome	  proliferator-­‐activated	  receptor	  gamma	  coactivator	  1-­‐alpha	  (PGC-­‐1	  α)	  is	  known	  as	  
the	  master	  regulator	  of	  mitochondrial	  biogenesis.	  PGC-­‐1α	  holds	  this	  role	  by	  acting	  as	  a	  transcriptional	  
coactivator	  for	  an	  array	  of	  transcription	  factors	  and	  nuclear	  hormone	  receptors,	  such	  as	  NRF-­‐1/2	  and	  
ERRα/γ,	  whose	  downstream	  targets	  function	  in	  mitochondrial	  biogenesis	  and	  oxidative	  phosphorylation.	  
PGC-­‐1α	  is	  regulated	  both	  at	  the	  transcriptional	  and	  post-­‐translational	  level	  in	  several	  signaling	  pathways,	  
including	  p38	  MAPK	  and	  AMPK.	  This	  regulation	  affects	  which	  transcription	  factor	  binding	  events	  can	  
occur	  in	  a	  given	  tissue,	  and	  thus	  affects	  regulation	  of	  PGC-­‐1α	  target	  genes.	  PGC-­‐1α	  is	  downregulated	  in	  
many	  neurodegenerative	  disorders	  as	  well	  as	  in	  muscular	  dystrophies,	  diabetes,	  and	  aging.	  Therefore,	  
PGC-­‐1α	  is	  prized	  as	  a	  potential	  therapeutic	  target	  to	  create	  novel	  treatments	  for	  these	  various	  diseases.	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However,	  details	  governing	  the	  spatio-­‐temporal	  regulation	  of	  PGC-­‐1α	  are	  not	  completely	  understood,	  
and	  overexpression	  of	  PGC-­‐1α	  throughout	  the	  body	  or	  even	  in	  certain	  tissues	  or	  subsets	  of	  cells	  have	  
had	  detrimental	  effects	  in	  animal	  and	  cell	  models.	  Therefore,	  it	  is	  necessary	  to	  gain	  knowledge	  of	  how	  to	  
modulate	  PGC-­‐1α	  in	  a	  tissue-­‐specific	  manner	  utilizing	  these	  different	  levels	  of	  regulation	  in	  order	  to	  
develop	  novel	  therapies.	  In	  order	  to	  further	  understand	  all	  the	  functions	  that	  have	  been	  attributed	  to	  
PGC-­‐1α,	  the	  PGC-­‐1α	  isoforms	  need	  to	  be	  accounted	  for	  and	  understood	  in	  human	  tissues.	  Several	  
murine	  isoforms	  have	  been	  published,	  as	  well	  as	  several	  human	  brain	  and	  muscle	  isoforms.	  However,	  
most	  of	  these	  isoforms	  have	  only	  been	  validated	  as	  mature	  transcripts,	  and	  it	  is	  not	  known	  whether	  they	  
produce	  functional	  protein.	  Our	  lab	  has	  identified	  the	  isoform	  b	  transcript	  in	  human	  brain	  tissue	  via	  5’	  
RACE	  and	  have	  developed	  an	  isoform	  b	  specific	  antibody.	  This	  project	  aimed	  to	  characterize	  the	  isoform	  
b	  transcripts	  and	  also	  to	  validate	  and	  optimize	  this	  antibody	  for	  immunoblotting	  conditions	  for	  detection	  
of	  further	  PGC-­‐1α-­‐b	  isoform	  protein	  variants	  in	  human	  tissues.	  Preliminary	  studies	  in	  our	  lab	  have	  
shown	  that	  in	  postmortem	  frontal	  cortex	  from	  age-­‐matched	  PD	  and	  healthy	  patients,	  isoform	  a	  
transcript	  levels	  were	  10-­‐15	  times	  more	  abundant	  than	  that	  of	  isoform	  b.	  These	  differences	  in	  regulation	  
could	  be	  partially	  attributed	  to	  the	  isoform	  b	  promoter	  region	  being	  heavily	  methylated,	  as	  shown	  in	  this	  
thesis	  through	  bisulphite	  cloning	  and	  sequencing	  as	  well	  as	  454	  bisulphite	  sequence	  analysis.	  The	  high	  
degree	  of	  methylation,	  correlated	  with	  the	  low	  level	  of	  isoform	  b	  transcript	  in	  brain	  and	  it	  is	  not	  known	  
whether	  this	  transcript	  would	  be	  translated	  into	  protein	  in	  this	  tissue.	  In	  order	  to	  probe	  for	  isoform	  b	  
protein	  expression	  using	  human	  cell	  lines	  and	  tissues,	  however,	  it	  was	  necessary	  to	  create	  a	  
recombinant	  protein	  in	  order	  to	  have	  a	  positive	  control	  with	  which	  to	  optimize	  our	  novel	  antibody.	  In	  
our	  previous	  5’	  RACE	  studies,	  an	  alternatively	  spliced	  PGC-­‐1α-­‐b	  transcript	  was	  found	  which	  coded	  for	  an	  
early	  stop	  codon.	  This	  truncated	  isoform	  was	  called	  PGC-­‐1α-­‐b-­‐3T1,	  and	  mature	  transcript	  was	  found	  in	  
both	  human	  skeletal	  muscle	  and	  brain.	  For	  this	  project,	  PGC-­‐1a-­‐b-­‐3T1	  was	  cloned	  from	  human	  skeletal	  
muscle	  into	  a	  bacterial	  expression	  vector	  to	  create	  a	  recombinant	  GST	  fusion	  protein.	  This	  protein	  was	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used	  to	  validate	  and	  optimize	  our	  PGC-­‐1α-­‐b	  specific	  antibody	  as	  well	  as	  to	  determine	  sensitivity	  and	  
specificity.	  The	  purified	  recombinant	  protein	  contained	  3	  bands	  of	  lower	  molecular	  weight	  that	  were	  
detected	  via	  western	  blot	  with	  both	  GST	  and	  the	  PGC-­‐1α-­‐b	  specific	  antibody.	  These	  bands	  were	  trypsin	  
cleaved	  and	  subjected	  to	  mass	  spectrometry	  analysis,	  which	  verified	  that	  all	  bands	  detected	  by	  the	  PGC-­‐
1a-­‐b	  specific	  antibody	  contained	  the	  epitope	  sequence,	  and	  thus	  binding	  was	  specific.	  This	  protein	  was	  
then	  used	  to	  determine	  western	  blotting	  conditions	  and	  sensitivity,	  which	  is	  10	  ng	  using	  a	  1:100	  dilution	  
of	  the	  antibody.	  This	  antibody	  was	  then	  used	  to	  probe	  SH-­‐SY5Y	  WCL,	  a	  human	  neuroblastoma	  cell	  line.	  
Peptide	  competition	  assay	  confirmed	  5	  PGC-­‐1α-­‐b	  specific	  proteins	  in	  these	  lysates.	  The	  sizes	  of	  these	  
proteins	  matched	  to	  several	  murine	  PGC-­‐1α-­‐b	  isoforms	  as	  well	  as	  putative	  PGC-­‐1α-­‐b	  versions	  of	  PGC-­‐1a-­‐
a	  isoforms.	  These	  findings	  provided	  the	  putative	  identities	  of	  several	  endogenous	  functional	  human	  
PGC-­‐1α-­‐b	  isoforms.	  Mammalian	  overexpression	  vectors	  of	  these	  isoforms	  are	  still	  in	  development.	  By	  
using	  this	  antibody	  and	  these	  expression	  vectors	  to	  further	  characterize	  these	  isoforms,	  including	  
determining	  tissue	  specificity,	  more	  knowledge	  of	  PGC-­‐1α	  will	  be	  gained.	  This	  information	  could	  then	  be	  
used	  to	  develop	  novel,	  tissue	  specific	  treatments	  for	  pharmacological	  intervention	  of	  diseases	  
characterized	  by	  PGC-­‐1α	  misregulation.	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Chapter 1: Introduction 
 
 
 
 
I. Overview of Mitochondrial Biogenesis  
 Mitochondrial biogenesis is the process by which new mitochondria are made in the cell. 
An increase in mitochondrial mass can either be a normal response to increase ATP production 
as needed, such as during exercise, formation of new cells, and fasting, or it can be stimulated 
as a rescue response to cellular stress, such as cold exposure, increased concentration of 
reactive oxygen species (ROS), or oxidative stress. Thus mitochondrial biogenesis is 
upregulated in healthy oxidative as well as abnormal states of metabolism. Considering that the 
mitochondrial genome only encodes 13 proteins, there are thousands of nuclear-encoded 
mitochondrial genes that must be transcribed, translated, and imported into mitochondria for it to 
carry out its functions and undergo biogenesis.  
 The major processes of mitochondrial biogenesis include transcription of nuclear-
encoded mitochondrial genes, importation of nuclear-encoded mitochondrial proteins, 
mitochondrial DNA replication and transcription, mitochondrial protein production and assembly, 
and ultimately mitochondrial fission and fusion (Fig. 1-1). The nuclear respiratory factors (NRF-
1, NRF-2) and other nuclear receptors (PPARs, ERRs) are responsible for the regulation of 
many nuclear-encoded mitochondrial genes required for mitochondrial biogenesis (Wu et al., 
1999). The translocases of the mitochondrial outer and inner membrane, TOM and TIM 
respectively, are primarily responsible for importation of these proteins into the mitochondrion 
(Kutik et al., 2007). For the mitochondrial encoded genes, TFAM (mitochondrial transcription 
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factor A) plays a major role their replication and transcription (Garstka, 2003)). Mitochondria can 
be thought of as a network rather than individual organelles, and thus the process of creating 
additional mitochondrial material to expand this network (mitochondrial biogenesis) is truly 
dynamic. This process is governed by mitochondrial fission and fusion, the breaking apart and 
joining of old and new mitochondrial material (Mozdy and Shaw, 2003). The mitofusins (Mfn1, 
Mfn2) are the proteins primarily responsible for mitochondrial fusion along with Opa1, whereas 
the dynamin-related proteins Drp1 and Fis1 are those involved in fission (Chen et al., 2003; 
Meeusen et al., 2006; Mozdy et al., 2000; Otsuga, 1998). Old and dysfunctional mitochondrial 
mass can be recycled via the process of mitophagy, completing the cycle of mitochondrial 
biogenesis (Lemasters, 2005).  
 Managing these processes requires much coordination between the nucleus and 
mitochondria to have correct levels and localization of necessary proteins at the correct times. 
The major family of proteins involved in coordinating all the events of mitochondrial biogenesis 
and metabolism are the PGC-1 (peroxisome proliferator-activated receptor γ coactivator-1) 
family of coactivators, including PGC-1α, PGC-1β, and PRC (PGC related coactivator) 
(Andersson and Scarpulla, 2001; Lin et al., 2002a; Puigserver et al., 1998) . PGC-1α, the most 
studied of this family, is known as the master regulator of mitochondrial biogenesis, which 
coordinates signaling input received during metabolic stress with transcriptional regulation for 
mitochondrial function and biogenesis (Wu et al., 1999). 
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Fig. 1-1: Overview of the major events of mitochondrial biogenesis (Adapted from (Ventura-Clapier et al., 2008). 
The major events include (1) transcription of nuclear encoded mitochondrial proteins, governed by PGC-1α / NRF-1/2 
binding interaction to upregulate genes involved in mitochondrial processes, which includes TFAM (2) Import of those 
proteins into the mitochondrion into their respective mitochondrial compartment by TOM and TIM (3) Transcription of 
mitochondrial-encoded mitochondrial proteins and replication of mtDNA by the imported TFAM – as well as polγ, 
polRM, among others – and assembly of those proteins (4) Mitochondrial dynamics of fission and fusion governed by 
Fis1 and Drp1 and Mfn1/2 and OPA1, respectively.    
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II. PGC-1α as the master regulator of mitochondrial biogenesis 
1. A history of PGC-1α and its family 
 A few decades ago while investigating adaptive thermogenesis, Puigserver and 
colleagues found that in mice PPARγ (peroxisome proliferator-activated receptor γ) activated 
uncoupling proteins (UCPs) only in brown adipose tissue (BAT) versus white adipose tissue 
(WAT). Using a mouse BAT cDNA library, they aimed to find the co-factor which was causing 
this activation. Over time, they were able to clone the novel protein responsible which they 
deemed PGC-1 (Puigserver et al., 1998). Renamed PGC-1α, it is a member of the PGC-1 family 
of transcriptional coactivators and was the first member of this family discovered. 
 Since then, two other members of the PGC family of coactivators have been identified. 
PGC-1β was found by its high degree of sequence homology to PGC-1α (Lin et al., 2002a). 
PRC does not share sequence homology with PGC-1α, but does bind PPARγ and also retains 
similar functional domains (Andersson and Scarpulla, 2001). In fact, these three family 
members share several important functional domains located at the N and C termini. These 
domains include an N-terminal transcriptional activation domain and C-terminal RNA processing 
motifs (RMM – RNA binding motif, RS - serine-arginine rich). This family differs from most 
coactivators in that the proteins themselves do not contain any enzymatic functions for 
chromatin remodeling and do not have homology to any other transcriptional coactivator families 
(Lin et al., 2002a). They can, however, recruit proteins with chromatin remodeling abilities 
through the NT activation domains, ultimately making the promoters of target genes accessible 
for transcriptional regulation. These recruited chromatin remodelers include CBP (CREB – 
cAMP response element binding protein - binding protein) and SRC-1 (steroid receptor 
coactivator-1), which both have histone acetyltransferase activity (Puigserver et al., 1998). The 
PGC-1 family also cannot bind DNA directly, but interact with DNA-binding partners to form 
transcriptional coactivator / transcription factor (TC/TF) binding pairs. Some of the common 
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transcription factors that interact with PGC-1 family coactivators are the NRFs (nuclear 
respiratory factors), TRs (thyroid receptors), PPARs (peroxisome proliferator-activated 
receptors), and the ERRs (estrogen related receptors) (Puigserver et al., 1998; Schreiber et al., 
2004; Vega et al., 2000; Wu et al., 1999).  
 Considering that the PGC-1 family shares so many transcription factor binding partners, 
it is not surprising that some of their functions overlap. However, common binding partners do 
not necessarily mean that the interaction will have the same downstream effect. Strength of 
binding will differ based upon structural hindrances due to amino acid sequence variability in the 
region surrounding the LXXLL transcription factor binding motif, amount of ligand present, as 
well as post-translational modifications (Lin et al., 2002a; McInerney et al., 1998; Nolte et al., 
1998; Westin et al., 1998). These factors can vary in different tissues among the common 
binding sites and can all affect the robustness of the transcriptional regulation and subsequent 
downstream interactions. This results in each member having some degree of overlapping but 
not entirely compensating functions for one another. For example, although each contributes to 
mitochondrial regulation and function, it is hypothesized that PGC-1α plays the most all-
encompassing role of the three in mitochondrial processes based upon its upstream position in 
modulating nuclear encoded mitochondrial effectors, thus it is known as the master regulator of 
mitochondrial biogenesis (Lin et al., 2002a; Wu et al., 1999). Also, PGC-1β specifically induces 
genes involved in ROS removal (St-Pierre et al., 2006). Differences in transcriptional regulation 
of the three family members affect where and when they can be expressed and exert their 
functions. For example, PRC is constitutively expressed equally among all tissue types, 
whereas PGC-1α and β are enriched in mitochondrially abundant tissue types; however, PGC-
1α is the only member of the family which can be induced by metabolic stress such as exercise, 
fasting, or cold (Meirhaeghe et al., 2003; St-Pierre et al., 2003). PGC-1β and PRC have not 
been studied extensively, unlike PGC-1α, and studies are still underway to determine all their 
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functional similarities and differences to PGC-1α.
 
Fig. 1- 2: Conservation of functional domains in the PGC-1 family of transcriptional coactivators (Adapted 
from Puigserver, 2003). (A) PGC-1α major functional domains include the activation, repression, and RNA processing 
motifs. LXXLL is a binding motif that typically allows binding to nuclear hormone receptor transcription factors, which 
grant PGC-1α its transcriptional coactivator ability. P = proline rich domain; HCF = host cell factor binding domain; RS 
= arginine / serine rich domain; RMM = RNA modeling motif. Phosphorylation sites (P balloons) are for p38 MAPK. 
(B) Conservation of domains in part A across the 3 members of the PGC-1 family of coactivators. 
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2. PGC-1α functional domains 
 There are several important functional domains of the PGC-1α protein. These include 
the NT activation domain, followed by a repression domain, a proline rich domain, and a host-
cell factor binding domain, ultimately ending in an RS domain and an RMM domain (see Fig. 1-
2). Moving from the N-terminus to the C-terminus, I will describe the features of each of these 
domains in more detail, including which areas can be targeted by post-translational 
modifications and how they contribute to PGC-1α regulation and function.   
 The activation domain (amino acids 1-200) contains many acidic amino acids. These 
allow it to interact with several potent transcription factors that contain chromatin remodeling 
activity, which PGC-1α itself lacks. These include SRC-1, CBP/p300, and GCN5.  One of the 
most important features of this functional domain is the LXXLL transcription factor binding motif. 
This motif grants PGC-1α its abilities as a transcriptional coactivator (see Fig. 1-2). There are 
three total LXXLL sites in PGC-1α. One lies within the activation domain, the remaining two 
within the repression domain, and are used to bind nuclear hormone receptors in the presence 
of ligand. These receptors include ER, PPARα, RXRα, GR, and SRC-1 (Delerive et al., 2002; 
Knutti et al., 2000; Puigserver, 1999; Tcherepanova et al., 2000; Vega et al., 2000). HNF4a is 
the only transcription factor binding partner of PGC-1α which can bind this motif in the absence 
of ligand (Yoon et al., 2001). PGC-1α also has a series of transcription factor binding partners 
which do not interact with PGC-1α via its LXXLL binding motifs. These include PPARγ and 
NRF-1, which bind amino acids 200-400 of the repression domain (Puigserver et al., 1998; Wu 
et al., 1999), and MEF2-C, which binds at amino acids 400-500 (Michael et al., 2001).  
 The repression domain, amino acids 200-403, was originally observed to have a 
repressive effect on the transcriptional activity of PGC-1α (Puigserver, 1999). A repressor 
protein, the p160 myb binding protein (p160MYB) was later shown to bind this regulatory 
domain, and was responsible for the repressive effect (Fan et al., 2004). When p38 MAPK is 
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activated via stress, it can phosphorylate PGC-1α in 3 different locations within this repression 
domain: T262, S265, and T298 (Puigserver et al., 2001). This phosphorylation increases the 
stability of PGC-1α and leads to an increase in transcriptional activity of PGC-1α target genes 
(Knutti et al., 2001). The repression domain also contains one of the nuclear localization signals 
for PGC-1α, located at amino acids 326-333, allowing it to translocate to the nucleus upon de-
repression as well (Monsalve et al., 2000).  
 The proline-rich domain follows the repression domain. While the function of this domain 
for PGC-1α has not been elucidated, proline-rich domains are commonly found in signaling 
proteins which contain multiple functional domains. Once bound to a transcription factor, for 
example, they typically function to guide the protein to assemble into complexes, with 
transcriptional complexes being a common target (Kay et al., 2000). Therefore, this proline-rich 
region is most likely involved in recruitment of PGC-1α to its transcription factor and chromatin 
remodeling binding partners gathered at the target gene's promoter. 
 The host cell factor (HCF) binding domain has been proposed to serve as a docking site 
for the host cell factor protein (Vogel and Kristie, 2000). HCF contains binding sites in several 
known PGC-1α transcription factor binding partners, such as NRF-2α and β. PGC-1α interaction 
with NRF-2 is necessary for its activation of some target promoters (Handschin et al., 2007a) 
(Lin et al., 2002).  However, the two proteins do not appear to interact directly, either in vivo or in 
vitro; HCF is therefore a likely candidate to promote the interaction between these factors for 
transcriptional activation (Lin et al., 2002a).      
 The C-terminal region of PGC-1α carries the RS and RMM domains. These two types of 
domains have been known to be involved in RNA processing, an uncommon feature of a 
transcriptional coactivator. These domains are specifically responsible for complexing with 
phosphorylated RNA polymerase II and elongation factors, providing a link between 
transcription and RNA processing (Monsalve et al., 2000; Yuryev et al., 1996). PGC-1α has also 
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been shown to be able to complex with several different splicing factors, and thus also has the 
potential to be involved in RNA splicing events, although most likely only to RNA derived from 
transcription target genes. There are also two nuclear localization signals located within the CT 
region (amino acids 627-633, 651-667). Interestingly, IHC for PGC-1α shows a “speckled” 
distribution of signal in the nucleus, a pattern that is typical of splicing proteins. This non-
homogenous intra-nuclear localization was shown to be dependent upon the RMM and RS 
domains (Monsalve et al., 2000). Thus, PGC-1α has the potential to both activate the 
transcription of its target genes and subsequently process the resulting transcript, although 
direct evidence for this latter activity is still circumstantial. 
 Several post-translational modifications control PGC-1α activity (Table 1-1). PGC-1α can 
be phosphorylated by p38 MAPK (Knutti et al., 2001; Puigserver et al., 2001). This 
phosphorylation is related to cytokine effects on PGC-1α and its effectors. AMPK can also 
directly phosphorylate PGC-1α, allowing PGC-1α to co-activate its own transcription (Jäger et 
al., 2007). When PGC-1α is deacetylated by NAD+ dependent SIRT1 deacetylase, PGC-1α can 
then bind to its transcription factors responsible for activation of fatty acid oxidation during 
fasting conditions, such as the orphan nuclear hormone receptors ERRα and ERRγ (Gerhart-
Hines et al., 2007). Arginine methylation across the length of PGC-1α by PRMT1 (protein 
arginine methyltransferase-1) can also activate PGC-1α (see Table 1-1). If any of these 
arginines are mutated, PGC-1α ability to regulate its target genes is negatively affected 
(Teyssier et al., 2005). 
 Although PGC-1α interacts with transcription factors that affect the downstream 
regulation of several target genes within a pathway, only some of those genes are induced by 
an interaction of that transcription factor with PGC-1α. This shows that there is promoter 
specificity for PGC-1α coactivational binding. For example, PPARγ can directly bind UCP-1 and 
Ap-2 (adipocyte protein-2) promoters and is a binding partner for PGC-1α. Upon coactivation 
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with excess PGC-1α, UCP-1 mRNA is upregulated, but the Ap-2 gene was not activated 
(Puigserver et al., 1998; Tontonoz et al., 1993). Thus, PGC-1α as a transcriptional coactivator 
not only increases a transcription factor's transcriptional activity, but also confers specificity to 
certain target genes. Also, chromatin immunoprecipitation studies on the ERs (estrogen 
receptors) indicates that the nuclear hormone receptors will bind different coactivators at 
different promoters. Therefore, promoters can lend specificity to certain transcriptional activator / 
coactivator pairs, and thus lead to the induction of different target genes (Shang et al., 2000).  
PGC-1α can have different binding partners due to interactions outside of the promoter region 
as well. This can occur by nuclear factors drawing it to enhancer or repressor regions in a target 
gene. For example, there are nuclear hormone receptors bound at the UCP1 (uncoupling 
protein 1) enhancer with which PGC-1α can interact depending on the presence of ligand. If 
ligand is present, PGC-1α can interact with the RAR (retinoid A receptor) or TR (thyroid 
receptor); without ligand, PGC-1α can interact with PPARγ (Puigserver et al., 1998). This leads 
to induction of different UCP-1 downstream targets, depending on the transcription factor pair 
that activated it.  
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Table 1-1. Post-translational modifications of PGC-1a 
Post-translational 
modification 
Responsible 
protein Location (aa) 
Functional 
Domain Reference 
Phosphorylation 
AKT S570 RNA processing Li et al., 2007 
AMPK T177, S538 Activation, RNA processing Jäger et al., 2007 
P38 MAPK T262, S265, T298 Repression 
Puigserver et al., 
2001 
Acetylation GCN5 K77, K144, 
K183, K253, 
K270, K277, 
K320, K346, 
K412, K441, 
K450, K757, 
K778 
Activation, 
repression, 
ligand-
independent 
binding, proline 
rich, RNA 
processing 
Lerin et al., 2006 
Deacetylation SIRT1 Rodgers et al., 2005 
Methylation PRMT1 R665, R667, R669 RNA processing Teyssier et al., 2005 
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Fig. 1-3: Transcriptional regulation and post-translational modifications of PGC-1α (Adapted from Wenz, 2013). 
The upper portion of the diagram indicates proteins which post-translationally modify PGC-1α. Pointed arrowheads 
represent a modification that leads to activation of PGC-1a, whereas flatheads indicate modifications that lead to 
inhibition of PGC-1α activity. Ac = acetylation; P = phosphorylation; Me = methylation. The lower portion of this 
diagram indicates proteins which affect gene expression, either by binding to or modifying the PGC-1α promoter. 
Pointed arrowheads represent of interactions that lead to upregulation of PGC-1a, whereas flatheads indicate 
interactions that lead to repression of PGC-1α expression. 
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3. Environment, stress, and diet: upstream PGC-1α regulation.  
 Several metabotropic receptor signaling pathway proteins are responsible for activating 
PGC-1α. These interactions can occur through a number of different interactions with various 
PGC-1α functional domains. All of these signaling proteins are initially stimulated by changes in 
concentrations of hormones, energy intermediates, or free radicals. These include glucagon, 
AMP, ROS, and NOS, among others. There are several routes through which PGC-1α can be 
regulated either at the level of post-translational modifications or gene expression (see Fig. 1-3, 
table 1-1). The enzymes responsible for post-translational modifications which result in 
alteration of PGC-1α activity include SIRT1, Akt, AMPK, and p38 MAPK (Table 1-1).  At the 
level of gene expression, there are both negative and positive regulators of PGC-1α mRNA. The 
positive regulators include the PPARs, CREB, and mTOR/YY1. The negative regulators include 
RIP140, 160myb, PARIS, DNMT3b, and p53. The details of these interactions and their 
regulatory roles on PGC1a levels and activity are under intense investigation.  
3a. Post-translational modifiers and regulators of PGC-1α activity:  
SIRT1: SIRT1 is a deacetylase of histones H3 and H4 and activates PGC-1α through this 
activity (Lagouge et al., 2006). Excess pyruvate in the diet (or lactate in the case of endurance 
exercise) leads to an increase in NAD+ concentrations. This provides substrate for SIRT1, 
which removes the acetyl group added to PGC-1α via GCN5 (Cantó and Auwerx, 2009).  This 
diet-dependent modification specifically upregulates PGC-1α activity in liver (Nemoto et al., 
2004; Rodgers et al., 2005). In addition, oxidative stress and SIRT1 deacetylation activate 
FOXO1 and FKHR (forkhead in rhabdomysarcoma) to bind to the PGC-1α promoter at its insulin 
response elements to promote its transcription (Daitoku et al., 2003; Frescas et al., 2005).  
Akt and AMPK: FOXO3 and Akt work to prevent nuclear translocation of FOXO1 and FKHR, 
respectively, and thus repress PGC-1α activation and mitochondrial biogenesis (Daitoku et al., 
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2003; Frescas et al., 2005). AMPK pathways serve in opposition to Akt pathways in that AMPK 
is activated in anabolic states (hypoxia, fasting, prolonged exercise) to promote catabolism, 
whereas Akt is activated in catabolic states to promote anabolism (Birnbaum, 2005). Exercise 
results in increased AMP, which activates AMPK, resulting in PGC-1α phosphorylation and 
mitochondrial biogenesis (Chabi et al., 2005). While short bouts of hypoxia stimulate AMPK and 
thus PGC-1α via NO synthesis, HIF-1 inhibits the AMPK pathway, suppressing mitochondrial 
biogenesis (Gutsaeva et al., 2008; Mason et al., 2007). 
p38 MAPK: β-adrenergic receptors innervated by the sympathetic nervous system are the first 
to regulate PGC-1α transcription in response to hypothermia and changes in diet (Puigserver et 
al., 1998). In response to oxidative stress or inflammation, these receptors along with cytokine 
cell surface receptors such as IL-1α, β, and TNFα, can directly phosphorylate p38 MAPK. This 
phosphorylation activates the PKA and p38 MAPK pathways via signaling cascades. PKA will 
eventually phosphorylate CREB, which can directly bind to the PGC-1α promoter to activate 
PGC-1α gene expression (Puigserver et al., 2001). Once p38 MAPK is activated, it can also 
phosphorylate PGC-1α directly. This causes a conformational change in the PGC-1α repression 
domain, thus destabilizing the repressive factor 160myb, which releases PGC-1α, making it 
active. Therefore, p38 MAPK phosphorylation ultimately activates and stabilizes PGC-1α, 
allowing it to translocate to the nucleus. Following exercise, p38 MAPK is stimulated in skeletal 
muscle. This stimulation results in the activation of transcription factors MEF2 and ATF2. ATF2 
upregulates PGC-1α expression and MEF2 functions as a TF binding partner for PGC-1α 
enabling activation of target genes. p38 MAPK can also directly phosphorylate PGC-1α in 
response to inflammation in muscle via cytokine signaling (Cao et al., 2004; Puigserver et al., 
2001). 
 
 
 15 
 
3b. Positive regulators of PGC-1α expression 
CREB (and MEF2): Exercise activates calcineurin (CaN) and Ca2+-calmodulin dependent 
kinase (CaMK) via contractile activity that increases the concentration of intracellular calcium. 
This rise in intracellular calcium causes CaMK to activate CREB in adipose tissue and muscle. 
CREB can then translocate to the nucleus to activate PGC-1α transcript expression in these 
tissues. TORC (transducer of regulated CREB-binding protein) can act as an enhancer for this 
interaction (Akimoto et al., 2004a, 2004b; Wu et al., 2006). CREB works to stimulate PGC-1α 
production in the nucleus via signal transduction of TORC1 and TORC2. TORCs respond to 
increases in calcium and cAMP in the cytosol and translocate to the nucleus to bind and 
activate CREB. In the nucleus, CREB then upregulates PGC-1α (Herzig et al., 2001; Wu et al., 
2006). In liver, CREB activates PGC-1α in response to glucagon, and in brown adipose tissue, 
CREB induces PGC-1α expression in response to cold temperature (Herzig et al., 2001; 
Puigserver et al., 1998). CaN functions and is activated similarly to CaMK. It can also indirectly 
activate PGC-1α in skeletal muscle, via activation of MEF2 (myocyte enhancer factor-2). MEF2, 
via interaction with its coactivator PGC-1α, is able to bind to the PGC-1α promoter and activate 
it; in this scenario, PGC-1α co-activates itself. (Handschin et al., 2003).  
PPARs: PPARs are able to detect dietary changes via their endogenous ligands such as fatty 
acids and eicosanoids. Via this ligand dependent binding, PPARs can associate with and 
activate PGC-1α and thus mitochondrial biogenesis (Gervois et al., 2000).  Fasting causes the 
expression of eNOS (endothelial NO synthetase), which causes NO production. NO stimulates 
mTOR and the FOXO transcription factors, which are regulators of PGC-1α. This ultimately 
activates PGC-1α and mitochondrial biogenesis (López-Lluch et al., 2006; Nisoli et al., 2005). 
YY1/mTOR:  It is possible for PGC-1α to self-regulate its gene expression via yin-yang 1 (YY1) 
as well. Through chIP assays, including overexpression and siRNA knockdown in cultured 
myotubes, it was determined that YY1 is a target of mammalian target of rapamycin (mTOR) 
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and PGC-1α. mTOR directly modulates the physical interaction of PGC-1α with YY1 and 
thereby modulates mitochondrial activity. mTOR is under the control of p53 and AMPK. Once 
stimulated via the AMPK signaling cascade, mTOR can complex with PGC-1α and YY1 
(Cunningham et al., 2007; Schieke et al., 2006). Decrease in mTOR activity by p53 likely inhibits 
YY1-PGC-1α function resulting in decreased expression of mitochondrial genes.   
3c. Negative regulators of PGC-1α 
RIP140: During adipogenesis, ERRα can also function to inhibit expression of PGC-1α via its 
ability to stimulate RIP140 (a nuclear corepressor). This represses both fatty acid oxidation and 
mitochondrial biogenesis. PGC-1α can also directly interact with RIP140 to repress ERRα and 
NRF-1 expression of CIDEA, a gene involved in apoptosis and metabolism. These interactions 
show negative feedback loops centering on PGC-1α in control of metabolism (Hallberg et al., 
2008; Nichol et al., 2006).  
PARIS: PARIS (ZNF746) is a zinc finger protein that was found to be a substrate for parkin, a 
protein in which mutations were found to be associated with PD. PARIS can repress the 
expression of PGC-1α and thus its target gene, NRF-1 by binding to IRS (insulin response) 
sequences in the PGC-1α promoter (Shin et al., 2012). Under normal circumstances, parkin 
regulates PARIS expression by binding to and ubiquitinating it. When parkin is dysfunctional, as 
in Parkinson’s disease, PARIS is no longer capable of being sequestered and degraded through 
parkin interaction, thus PGC-1α repression occurs in an uncontrolled and detrimental manner.  
p53: Shortening of telomeres occurs as a result of aging. This shortening activates the 
telomere- p53 pathway, which results in p53 binding and repression of PGC-1α and β 
transcription (Sahin et al., 2013). 
DNMT3b: The PGC-1α promoter can be methylated by DNMT3b to repress its expression 
(Barrès et al., 2009). This was found to occur when levels of palmitate, a free fatty acid, were 
high, inducing the non-CpG methylation of the PGC-1α promoter. This resulted in decreased 
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PGC-1α as well as mtDNA levels.  
4. PGC-1α binding partners and downstream signaling 
 Once PGC-1α has been activated or derepressed by the several pathways described, it 
can carry out its function as a transcriptional coactivator and form complexes with its 
transcription factor binding partners at the promoters of its target genes. The main families of 
binding partners PGC-1α interacts with include the NRFs, ERRs, and the PPARs. These 
families of binding partners mainly function in mitochondrial biogenesis, but all other functions 
have a main theme of oxidative metabolism (see Fig. 1-4). These include fatty acid oxidation, 
peroxisome function, glucose sensing and utilization, as well as free radical detoxification.  
Other functions that operate outside of oxidative metabolism include osteogenesis, 
neuromuscular junction stabilization, adipocyte cell fate, and myotube cell fate.  
NRFs:  PGC-1α activates the expression of subunits of the respiratory chain and TFAM through 
the induction of NRFs and the coactivation of NRF-1-mediated transcription. TFAM 
subsequently translocates into the mitochondrion and directly increases the transcription and 
replication of mtDNA necessary for mitochondrial biogenesis (Evans and Scarpulla, 1990; 
Virbasius et al., 1993; Wu et al., 1999). The NRF-1/ PGC-1α transcription factor / coactivator 
pair (TF/TC) can also target VHL (von Hippel-Lindau tumor suppressor), a negative regulator of 
HIF-1. HIF-1 can function to suppress AMPK signaling pathways, which would cause a 
decrease in overall PGC-1α expression; however, the activation of VHL would prevent this 
decrease in non-disease states (Hervouet et al., 2005). PGC-1α also interacts with NRF-2α. 
This TF/TC pair targets and thus induces β-ATP synthase in addition to the nuclear-encoded 
mitochondrial cytochrome C genes (Mootha et al., 2004). These interactions show that the 
NRF/PGC-1α binding pair is crucial for mitochondrial biogenesis and preservation of normal 
mitochondrial function. Our lab discovered the mitochondrial DNMT1 isoform, which is 
transported into the mitochondrion via a mitochondrial leader sequence. Once in the 
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mitochondrion, mtDNMT1 can methylate mitochondrial DNA (Shock et al., 2011). Our lab also 
found that mtDNMT1 is a target of the PGC-1α / NRF1 TC/TF binding pair. This was shown via 
immunoblot where mitochondrial levels of DNMT1 increased after cotransfection of PGC-1α and 
NRF1 (Shock et al., 2011). These findings show that PGC-1α plays an indirect role in the 
methylation and subsequent epigenetic regulation of mitochondrial DNA. 
ERRs: The ERRs are orphan nuclear hormone receptors. When bound to PGC-1α, ERRα and 
ERRγ can target genes involved in the scavenging, production, and transport of ATP and its 
precursors across the mitochondrial membranes as well as intracellular fuel sensing (Dufour et 
al., 2007). ERRα controls MCAD (medium chain acyl-coenzyme A dehydrogenase) to promote 
β-oxidation of fatty acids and thus also provide reducing equivalents NADH and FADH2 for the 
respiratory chain. This TC/TF pair also controls several genes important for mitochondrial 
biogenesis. PGC-1α also utilizes ERRα to create a positive feedback loop. This is possible 
because the ERRα promoter can bind NRF2 and itself to activate its own transcription. ERRα 
can subsequently bind PGC-1α to upregulate NRF-1 (Mootha et al., 2004; Schreiber et al., 
2003). ERRγ is similarly activated by PGC-1α, except its target genes lie in areas of glucose 
sensing as well as fatty acid oxidation during fasting conditions (Gerhart-Hines et al., 2007). 
PPARs: Both PPARα and PPARγ function as binding partners for PGC-1α.  PGC-1α / 
transcription factor pairs function to target a series of tissue specific promoters to mediate 
different controls of metabolism. In adipose tissue, PGC-1α is activated in response to 
environmental cold via β-adrenergic receptors functioning in response to the temperature 
change triggered by the sympathetic nervous system. Once PGC-1α is activated in this tissue, it 
coactivates PPARγ and TH (thyroid hormone receptor) on the UCP1 enhancer. This interaction 
ultimately leads to BAT-mediated adaptive thermogenesis in mammals (Fan et al., 2004; 
Puigserver et al., 1998). PGC-1α stimulates genes of fatty acid oxidation in cardiac cells as well 
as in adipocytes via its binding interaction with PPARα (Barger et al., 2000). PPARα regulates 
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Fig. 1-4: PGC-1α binding partner interaction and downstream regulation (Adapted from Wenz, 2011). The left 
side of this diagram follows the same logic as in Fig. 1-3. (moving from left to right) After PGC-1α is regulated at the 
transcript or protein level, PGC-1α-protein can interact with its transcription factor binding partners through their 
respective domains (see Fig. 1-2). PGC-1α can now indirectly bind to the target gene of the pair and up or 
downregulate expression. These target genes are involved in an array of processes including mitochondrial 
biogenesis and oxidative phosphorylation.  
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carnitine O-palmitoyltransferase-1 in this β oxidation process (Vega et al., 2000). This provides 
reducing equivalents NADH and FADH2 for the respiratory chain, contributing to mitochondrial 
function and biogenesis.  
 
Other targets functioning in oxidative metabolism: 
 PGC-1α induces the gene expression of Glut4 (insulin sensitive glucose uptake 
transporter), increasing glucose uptake; this connection is mediated through PGC-1α binding to 
the transcription factor MEF2C (myocyte enhancer factor-2C) (Michael et al., 2001). YY1 is an 
initiator element-binding factor which can be activated via interactions with mTOR and PGC-1α 
as previously detailed. It can both enhance and suppress certain cytochrome oxidase subunit 
genes important in mitochondrial biogenesis (Seelan and Grossman, 1997).  Thyroid hormone 
response elements in the PGC-1α promoter can bind thyroid hormone and thus coactivate and 
upregulate thyroid hormone receptor (TR) (Weitzel and Iwen, 2011). PGC-1α also controls 
peroxisome biogenesis. This is interesting to note, because mitochondria and peroxisomes work 
together to carry out oxidative metabolism, with peroxisomes providing partially broken down 
fatty acids for complete breakdown to their energy equivalents via β-fatty acid oxidation by 
mitochondria (Bagattin et al., 2010). PGC-1α may also localize to the mitochondria to directly 
coordinate the induction of mitochondrial genes via interactions with TFAM (Aquilano et al., 
2010; Safdar et al., 2011). PGC-1α also co-activates expression of mammalian homolog of 
tribble3 (TRB-3), an Akt pathway inhibitor (Koo et al., 2004)(O’Hagan et al., 2009). This is 
interesting since Akt phosphorylation can repress PGC-1α. PGC-1α target genes also include 
genes regulated by HIF-1α (O'Hagan et al., 2009). When there is sufficient oxygen, PGC-1α is 
able to induce HIF-1α responsive genes by stabilizing HIF-1α. It has been recently shown that 
this may be a tissue specific interaction, in that PGC-1α is required to regulate the response of 
adipocytes (Pino et al., 2012) as well as endothelial and neuronal cells under hypoxic conditions 
(Zhao et al., 2012). 
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 PGC-1α has several targets that function in antioxidant production and ROS 
detoxification. One of these targets is SIRT3 (Kong et al., 2010). Once induced, SIRT3 localizes 
to the mitochondria to aid in mitochondrial biogenesis by regulating metabolic enzymes and 
ROS detoxification (Verdin et al., 2010). SIRT3 can also target the mitochondrial permeability 
transition pore (mPTP, referred to in this work as VDAC). Once activated, it regulates cyclophilin 
D and prevents the pore from opening. This pore plays a role in apoptosis and mitophagy, thus 
SIRT3 provides an additional downstream function for mitochondrial stability. SOD2 (superoxide 
dismutase) and GPX1 (glutathione peroxidase), also activated by PGC-1α, assist in the removal 
of superoxide and hydrogen peroxide (St-Pierre et al., 2003, 2006; Valle et al., 2005). The 
FOXO transcription factors function as binding partners for PGC1α, particularly FOXO3. FOXO3 
target genes require coactivation by PGC-1α to be induced. These include ROS detoxifying 
proteins (Olmos et al., 2009).  
Targets functioning outside of oxidative metabolism: 
In complex with NRF-2α (GABP), PGC-1α can upregulate genes involved in neuromuscular 
junction function (Handschin et al., 2007b). PGC-1α can also control VEGF expression and thus 
contributes to muscle angiogenesis (Chinsomboon et al., 2009). Through interaction with ERRα 
as well as coactivation of the vitamin D receptor, PGC-1α may play an important role in bone 
formation and maintenance (Savkur et al., 2005; Zirngibl et al., 2008).  
Overall, PGC-1α binding interactions regulate the transcription of its downstream target 
genes. This transcriptional regulation is key to producing the proteins necessary to govern all 
aspects of mitochondrial biogenesis. This role of master regulator which PGC-1α holds is truly 
demonstrated in its ROS management activity. Since PGC-1α activity can result in increased 
mitochondrial mass, PGC-1α indirectly induces naturally increased levels of ROS. This increase 
could be detrimental to the cell, but PGC-1α is able to upregulate genes involved in antioxidant 
production and ROS detoxification, compensating for its own potential negative effects. 
Therefore proper PGC-1α function in mitochondrial biogenesis and ROS management is crucial 
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to the maintenance of cell health.  
III. PGC-1α: animal and cell models 
Over the past 15 years, animal and cell models have been developed as tools to elucidate the 
overarching processes controlled by PGC-1α. Many of these models also gave insight into the 
genes up or downregulated by the overexpression or absence of PGC-1α and thus the 
pathways controlled by PGC-1α. Immunoprecipitation using tissue from transgenic mice as well 
as cell lines overexpressing PGC-1α also allowed identification of binding partners. Although the 
pathways involved and binding partners have already been described here, I will provide an 
overview of the findings of PGC-1α animal and cell models that are available and point out how 
these studies gave insight into potential roles of PGC-1α in mitochondrial dysfunction and 
disease. 
1. Knock out and silencing studies 
 PGC-1α null mice, created using a Cre-Lox system with a ZP3 promoter, resulted in directing 
homologous recombination removing exons 3-5 of the PGC-1α gene to oocytes, thus driving the 
deleted allele into the germline. Breeding of mice heterozygous for the null allele resulted in 
homozygous PGC-1α null mice. Under normal conditions germline PGC-1α knockout mice are 
viable and appear to function normally; however, under stress they cannot maintain body 
temperature and are unable to maintain energy production or cardiac output (Arany et al., 2005; 
Leone et al., 2005; Lin et al., 2004). As a result, these mice are very sensitive to cold exposure, 
becoming hypothermic to the point of death in a short period (Leone et al., 2005; Lin et al., 
2004). This is a direct consequence of the requirement for PGC-1α in adaptive thermogenesis 
in brown fat via targeting of UCP1 through activation of TR and PPARγ. PGC-1α KO animals 
also showed deficits in converting from fed to fasted state, resulting in hypoglycemia and 
hepatic steatosis (Koo et al., 2004; Leone et al., 2005). Since PGC-1α is responsible for 
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mediating all metabolic changes in the liver during fasting, including gluconeogenesis and fatty 
acid β oxidation, this result would also be expected (Yoon et al., 2001). 
In addition to metabolic stress related changes, behavioral and cell morphological 
changes were also observed in these mice. The behavioral changes include increased anxiety 
and hyperactivity, which causes the mice to be very lean and have difficulty gaining weight. The 
brains of knockout mice showed distinct morphological changes, including vacuolizations 
localized mainly to the dorsolateral striatum but also seen sporadically throughout the brain (i.e. 
cortex, thalamus, basal ganglia, and hippocampus), accompanied by reactive glia and 
neurodegeneration (Leone et al., 2005; Lin et al., 2004). Another feature of the brains of these 
PGC-1α global knockout mice is that the neurons in the substantia nigra and the CA1 of the 
hippocampus are more susceptible to chemically induced neurodegeneration, such as from 
MPTP and KA (St. Pierre et al., 2006). As another potential cause for these abnormalities and 
the inability to maintain homeostatic functions under stress, real-time RT-PCR of these mice 
revealed vast decreases in levels of mitochondrial genes (Lin et al., 2004).  
            Conditional knockouts of PGC-1α have been accomplished using tissue specific Cre 
recombinase.  The KOs generated were specific to mouse forebrain and mouse skeletal 
muscle. By deleting PGC-1α in CaMKIIα expressing neurons, Ma and colleagues were able to 
investigate the role of PGC-1α in the forebrain (Ma et al., 2010).  These mice had many similar 
characteristics to the global PGC-1α knockout mice, except they were able to maintain certain 
functions that operated outside of the CNS, such as habituation to cold and fasting (brown 
adipose tissue and liver, respectively). Similarly to the global KO mice, the forebrain KO mice 
retained neurodegeneration in the striatum as well as resistance to obesity due to increased 
metabolic rate. Therefore, the majority of the function of PGC-1α in these neurons was 
attributed to maintaining neuronal stability and energy balance.  
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In skeletal muscle-specific PGC-1α KO mice, cytokine TNF-α levels of transcript and 
protein were increased following acute endurance exercise (Handschin et al., 2007c). A 
reduction in levels of antioxidant genes was also observed in these muscle-specific knockouts 
(Valle et al., 2005). These included reduced mRNA levels of SOD1, SOD2, and GPx1 with 
reductions in SOD2 protein levels as well (Geng et al., 2010; Leick et al., 2010). This provides 
evidence that one of the roles of PGC-1α is to prevent inflammation in response to metabolic 
stress. PGC-1α knockdown models have been developed as well, which have similar 
phenotypes to the PGC-1α KO models. PGC-1α knockdowns in mice are characterized by a 
reduced capacity for exercise, inability to maintain glucose and insulin levels, inflammation, and 
muscle fiber damage during exercise (Handschin et al., 2007b, 2007c). A knockdown model 
specific to human pancreatic islets was also created. siRNA knockdown of PGC-1α expression 
in human pancreatic islets resulted in a reduction in insulin secretion (Ling et al., 2008). This 
provides evidence that PGC-1α aids in normal pancreatic function and glucose sensing, and 
therefore its dysregulation may play a significant role in diabetes.  
2. Overexpression studies 
            From studies involving overexpression of PGC-1α, there is proof of spatial regulation, 
i.e. tissue-specific effects, as well as temporal regulation, i.e. age-specific effects. This spatio-
temporal regulation could potentially be controlled via epigenetics. Overexpression of PGC-1α 
can be harmful in the incorrect space and time, having similar effects to PGC-1α KO mice. For 
example, overexpression of PGC-1α in mice causes cardiac myopathy (Barger et al., 2000). 
When PGC-1α was overexpressed in the rat nigrostriatal tract, neuron degeneration was 
observed in dopaminergic cells of the substantia nigra pars compacta (SNp)  (Ciron et al., 
2012), a result that was similar to that obtained with tissue-specific KO mice. Therefore too 
much or too little PGC-1α can be equally detrimental.     
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            Overexpression can be beneficial, however, in the correct space and time. During 
development, elevated levels of PGC-1α are natural. In older mice transgenically 
overexpressing PGC-1α,  PGC-1α inhibits FoxO3 activity to upregulate genes involved in 
denervation and muscle atrophy, resulting in a decrease in muscle wasting as a response to 
aging (Sandri et al., 2006; Wenz et al., 2009).  When overexpression is targeted to specific 
tissues for short periods PGC-1α effects are also beneficial. For example, overexpression of 
PGC-1α in the skeletal muscle of transgenic mice promotes the conversion to slow, oxidative 
type I and IIA muscle fibers. This is accompanied by the induction of oxidative phosphorylation 
and fatty acid oxidation genes along with increased mitochondrial mass (Lin et al., 2002b). In 
studies of mice ectopically expressing PGC-1α in muscle (MCK-PGC-1α transgenics), it was 
seen that mitochondria isolated from muscle of these mice vs. wild-type mice had a higher 
capacity for respiration and also preferred different substrates (lipids vs. carbohydrates) for that 
respiration (Hoeks et al., 2012; St-Pierre et al., 2003). This shows that new mitochondria 
created from PGC-1α induction have different properties than those not influenced by activation 
of PGC-1α. The converse is also true in PGC-1α deficient mice (Zechner et al., 2010). These 
changes could be due to differences in levels of protein necessary for respiration in these 
animals, such as increases in citrate synthase and β-hydroxyacyl CoA dehydrogenase (Hoeks 
et al., 2012). This phenomenon is referred to as organelle remodeling.  
The mitochondria of the MCK-PGC-1α Tg mice, despite having higher levels of 
mitochondrial ROS production than their WT counterparts, show decreases in oxidative damage 
over time. This is due to subsequent PGC-1α upregulation of detoxifying enzymes that clear the 
ROS, which outweighs the extra being produced. This is further supported by increased levels 
of circulating ROS and oxidative damage in muscle from PGC-1α null mice. This increase in the 
amount of ROS produced initially compared to WT in the Tg mice is believed to be due to PGC-
1α transcription modulation to increase the amount of complex I and complex III expressed in 
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the new mitochondria (Austin et al., 2011; St-Pierre et al., 2006; Valle et al., 2005; Wenz et al., 
2009). In cultured cells, overexpression of PGC-1α increases protein levels of COXIV and 
Cytochrome C, and increases mtDNA copy number (Wu et al., 1999). Other beneficial effects of 
PGC-1α overexpression include up-regulation of SOD2 protein content, decreased inflammatory 
cytokine production, and decreased protein degradation due to denervation as observed in 
mouse skeletal muscle (Sandri et al., 2006; Wenz et al., 2009).  These tissue-specific effects 
together with the fact that PGC-1α is highly expressed during development and then decreases 
shows that there are both spatial and temporal changes in PGC-1α regulation over an 
organism's lifetime. These changes could potentially be modulated via epigenetics and 
epigenetics based therapeutics. If overexpression could be targeted to certain tissues where an 
overabundance of PGC-1α is beneficial, its therapeutic effects could be harnessed.  
 
IV. PGC-1α: Potential therapeutic interventions 
If PGC-1α would be targeted therapeutically, it could not be done so directly. As demonstrated 
in animal and cell models, too little or overly excessive levels of PGC-1α can be harmful. 
Therefore directly targeting PGC-1α in order to drastically increase or decrease overall body 
levels would be similarly detrimental. Rather, drugs targeted to transcriptional regulation, protein 
modifications, or binding partner interactions of PGC-1α should be developed. Ideally, tissue-
specific interactions in these three areas would be targeted to modulate levels of PGC-1α in a 
disease relevant manner. If drastic changes in protein levels were necessary to ameliorate 
dysfunction, administering tissue-specific PGC-1α targeting therapies would prevent detrimental 
effects in other tissues. The major classes of diseases with which PGC-1α has been associated 
include aging and muscle dysfunction, diabetes, and neurodegenerative diseases. I will 
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describe below the connections that PGC-1α has to several diseases and what therapeutic 
strategies are currently being considered that revolve around these connections. 
 
Aging and Muscle Dysfunction:       
Prolonged inactivity can result in muscle wasting, as seen in aging and muscle dysfunction 
diseases. This inactivity (IM) results in a natural loss of PGC-1α in skeletal muscle (Shin et al., 
2012). Even when muscle movement is restored (RM), in cases of return to mobilization after 
rehabilitation, the body responds with increased ROS, cytokine, and oxidative stress levels, 
presumably due to the lag phase of PGC-1α attempting to return to normal levels (Kang and Ji, 
2013). This response actually slows rebuilding of the muscle and functional rehabilitation. In a 
recent study in mice, it was found that local overexpression of PGC-1α after IM followed by RM 
lowered the initial inflammatory response naturally incited by RM while increasing mitochondrial 
biogenesis and oxidative phosphorylation (Kang and Ji, 2013).  
Studies have shown that both endurance and resistance training can improve the aging 
phenotypes of human skeletal muscle. Exercise induces PGC-1α levels (Feng et al., 2013; 
Matiello et al., 2010; Suwa et al., 2008). Interestingly, older adults who regularly performed 
resistance type exercise had transcriptomes that were more similar to young adults than to less 
active people of their same age group, including elevated PGC-1α levels (Handschin and 
Spiegelman, 2008). It was shown in old mice as well that not only continuous participation in 
exercise training could result in this pro-PGC-1α young muscle phenotype, but even short 
periods of training can restore PGC-1α levels and increase mitochondrial biogenesis, and thus 
mtDNA content and ATP production in older mice (Kang and Ji, 2013).    
Mutant POLG mice (polymerase γ, the only polymerase that transcribes mtDNA), exhibit 
early aging phenotypes including decreases in mitochondrial number and function. When these 
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mice also transgenically overexpress PGC-1α, mitochondrial activity increases, improving 
cardiac and muscular function, including decreases in sarcopenia (Dillon et al., 2012) This 
shows that PGC-1α can function to reduce or delay the mitochondrial dysfunction that 
contributes to aging. In mice, transgenic elevation of PGC-1α in muscle reduces muscle fiber 
atrophy induced by statins, as well as in models of Duchenne muscular dystrophy and 
mitochondrial myopathy (Hanai et al., 2007; Handschin et al., 2007b; Sandri et al., 2006). This is 
presumably due to overexpression of PGC-1α inducing an exercised phenotype, which is 
potentially due to its role in the control of neuromuscular junction genes as well as muscle fiber 
type switching. Together, these studies show that exercising regularly can improve muscle 
function and prevent muscle wasting associated with aging as well as muscle dysfunction 
diseases via increases in PGC-1α and mitochondrial biogenesis.   
Diabetes and Obesity: 
PGC-1α expression has been shown to be reduced in WAT (white adipose tissue) of morbidly 
obese and diabetic patients (Semple et al., 2004; Yang et al., 2003)(Patti et al., 2003). It was 
also found that early signs of insulin resistance included reduced levels of PGC-1α, NRF1, and 
mtDNA (Patti et al., 2003). This was determined to be due to hypermethylation of PGC-1α 
potentially achieved through environmental changes, such as a buildup of fatty acids in the diet 
(Barrés et al., 2009). Although demethylases do exist, there are no ways as of yet to target them 
to particular promoters. Therefore activating PGC-1α has been the only therapeutic strategy in 
relation to the connection of PGC-1α to diabetes that has been used in the treatment of this 
disease. Fibrates and thiazoledinediones are currently in use (PPAR activators; (Wilson-fritch et 
al., 2004)). Also, with the various important roles in metabolism for PGC-1α, including glucose 
sensing, it could be a pharmacological target for developing new drugs to treat diabetes or 
obesity. 
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NEURODEGENERATIVE DISEASES 
Some evidence has shown that reactive oxygen species (ROS) may play a protective role in 
metabolism by stimulating mitochondrial biogenesis. In fact, levels of ROS and reactive nitrogen 
species (RNS) produced during exercise activate the specific PGC-1α pathway that stimulates 
antioxidant production. This system is likely disrupted in neurodegenerative diseases, resulting 
in detrimental effects (Gomez-Cabrera et al., 2008; St-Pierre et al., 2006).  
Huntington's Disease (HD) 
In HD patient brain, there is a reduction in PGC-1α mRNA and protein levels (Cui et al., 2006; 
Taherzadeh-Fard et al., 2009; Weydt et al., 2006), which is also apparent in a transgenic mouse 
model of HD (Cui et al., 2006). The transgene introduced in mouse contains the 5’ end of 
human mutant Huntington gene, through exon 1. Within this portion of the transgene, transcript 
encoding for CAG repeats, aka the polyglutamine tract, is expanded compared to normal 
Huntington protein. This region is variable from animal to animal of the same species, with a 
normal protein containing about 30 glutamine repeats. Once this variable region expands 
(through unknown means) over generations to >115 glutamine repeats, this protein exhibits a 
toxic gain of function, resulting in Huntington’s Disease. This expanded number of glutamine 
repeats from ~27 to 115-150 in the transgene induces an HD phenotype, resulting in HD model 
mice (Mangiarini et al., 1996), PGC-1α KO mice as well as these HD transgenic mice exhibit the 
same behavioral and neuro-morphological abnormalities that are seen in Huntington's Disease 
patients, including choireform movements, tremor, epileptic seizures, and spongiform striatum 
(Cui et al., 2006; Lin et al., 2004; Weydt et al., 2006). In HD mice, exogenous restoration of 
PGC-1α expression via lentiviral vectors maintained the morphological integrity of the striatum 
(Cui et al., 2006). PGC-1α overexpression in these HD mice rescues neurons from altered 
morphology, degeneration and apoptosis, as well as mitochondrial dysfunction (Cui et al., 
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2006).  Therefore, maintenance of proper PGC-1α levels is important to neuron function and 
viability, specifically those neurons residing in the most highly affected area of both the PGC-1α 
KO mice and Huntington's patients: the striatum. Although the mechanics are unknown, the 
disease etiology is believed to be caused partially by PGC-1α repression by the mutant form of 
Huntington protein. This PGC-1α downregulation seen in these studies results in alteration of its 
downstream functions, particularly the maintenance of mitochondrial processes. Mitochondrial 
fragmentation is also observed in the striatal neurons of these HD mice, which is a sign of a pre-
apoptotic cell (Kaddour-djebbar et al., 2010; Wang et al., 2009).This mitochondrial dysfunction 
may or may not be directly due to loss of PGC-1α, but it does present a likely possibility.  PGC-
1α ultimately regulates transcription of proteins necessary for mitochondrial dynamics, including 
Drp1 which is integral to the mitochondrial fragmentation process that can lead cells into an 
apoptotic state (Kaddour-Djebbar et al., 2010).  Considering this connection as well as evidence 
in PGC-1α KO models of the importance of PGC-1α to maintaining the integrity of neurons in 
the striatum points to PGC-1α repression being a leading cause of HD, and more specifically, its 
role in the mitochondrial dynamics aspect of mitochondrial biogenesis.  
Parkinson's Disease 
Several studies have linked PGC-1α to Parkinson's Disease pathogenesis. A gene set 
enrichment analysis of 17 independent microarray datasets of human PD samples found that 
425 PGC-1α regulated genes were down-regulated in this disease (Zheng et al., 2010). These 
genes were all found to be affected in substantia nigra homogenates as well as laser captured 
substantia nigra dopaminergic neurons gathered post-mortem from asymptomatic PD 
(incidental Lewy bodies) as well as symptomatic late stage PD patients. Their analysis indicated 
that the processes of mitochondrial electron transport, glucose utilization, and glucose sensing – 
all linked by PGC-1α – are misregulated early on in Parkinson's Disease pathology (Zheng et 
al., 2010). 
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            Another link between PGC-1α and Parkinson's Disease is PARIS (ZNF746). PARIS is a 
zinc finger protein which can act as a substrate for parkin, a protein known to be associated with 
PD when mutated. PARIS can repress the expression of PGC-1α and thus its target gene, NRF-
1. When parkin is conditionally knocked-out in mice, loss of dopaminergic neurons is observed. 
This neuron-specific neurodegeneration increases upon higher expression of PARIS. Cell loss 
was rescued by the addition of either parkin or PGC-1α (Shin et al., 2011). This exhibits the 
neuroprotective effects of PGC-1α, which was also observed in cell culture models of PD 
(Wareski et al., 2009; Zheng et al., 2010). The PARIS/PGC-1α interaction provides insight into 
PD pathology. PARIS interacts with PGC-1α at IRSs (insulin response sites) which regulate 
transcripts associated with insulin responsiveness and energy metabolism (Mounier and 
Posner, 2006). This relationship may connect mitochondrial dysfunction and improper glucose 
utilization to PD.  A potential treatment that has emerged to target PGC-1α in PD is resveratrol. 
Resveratrol is a SirtI activator, which is involved in activating PGC-1α control of glucose sensing 
genes. By using it to activate PGC-1α in degenerating dopaminergic neurons, resveratrol 
rescued the cells, as did overexpression of PGC-1α (Mudò et al., 2012). Therefore, resveratrol 
has neuroprotective effects on dopaminergic neurons due to its downstream activation of PGC-
1α, and thus is a potential therapy for attenuating the neurodegenerative effects of PD. 
Alzheimer's and ALS 
PGC-1α control of glucose utilization seems to play a role not only in PD, but also in AD 
pathogenesis (Qin et al., 2009). In neurons of an AD mouse model, these investigators showed 
a dose-dependent relationship between high glucose and β-amyloid plaque formation. This 
dose-dependent relationship also applied to PGC-1α expression: the higher the glucose 
concentration, the lower the PGC-1α.  This provided a direct relationship between glucose 
utilization and AD pathology, linked together by PGC-1α. Upon exogenous addition of PGC-1α 
under these same hyperglycemic conditions, β-amyloid plaque formation was stopped. The root 
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of this process was found to be that hyperglycemic PGC-1α suppression in PD derepressed the 
FOXO3a transcription factor, thus contributing to β-amyloidogenic cutting by α-secretase (Qin et 
al., 2009).    
            PGC-1α is underexpressed in AD patients and mouse models. In cell models of AD, 
when PGC-1α is overexpressed, the phenotype returns to that of a non-disease state (Qin et al., 
2009; Sheng et al., 2012). This shift occurs in mouse models of ALS as well upon expression of 
PGC-1α (Da Cruz et al., 2012; Liang et al., 2011; Zhao et al., 2012).           
            Similarly to its effects on dopaminergic neurons in PD, resveratrol offers neuroprotection 
to hippocampal neurons in a mouse model of AD through indirect activation of PGC-1α via Sirt1 
(Kim et al., 2007). Reseveratrol is therefore a potential future therapy for AD, by its link to PGC-
1α.  Some drugs inadvertently targeting PGC-1α are already available and may be beneficial in 
diseases for which the drugs were not initially developed. These include fibrates and 
thiazoledinediones (PPAR activators), resveratrol (Sirt1 activator), as well as metformin and 
AICAR (AMPK activators). 
V. Emerging PGC-1α isoforms 
            As of this year, there have been a total of 19 published PGC-1α isoforms (see table 1-2, 
Fig. 1-5). This number includes the canonical isoform, henceforth PGC-1α-a, of which all the 
information laid out in this introduction up until this point has been based upon. Although 19 
exist, they can be broken into a few different categories based upon the promoter utilized to 
form the transcript. This list includes 4 PGC-1α-a variants  (Puigserver et al., 1998; Soyal et al., 
2012; Zhang et al., 2009), 3 PGC-1α-b variants (Miura et al., 2008; Ruas et al., 2012), 2 PGC-
1α-c variants (Miura et al., 2008; Ruas et al., 2012), 1 NT-truncated (Felder et al., 2011), and 9 
NT-extended (Choi et al., 2013; Soyal et al., 2012). 
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PGC-1α-a variants: Thus far, other than the canonical form of PGC-1α, there have been 3 
other variants reported. These include NT-PGC-1α (Zhang et al., 2009), PGC-1α ex1-3ext and 
PGC-1α ex1-8a (Soyal et al., 2012). While PGC-1α ex1-3ext and 8a are the most recent isoform 
a variants to be identified, little is known about them. These two novel isoform a splice variants 
were found in human brain tissue via 5' RLM RACE (Soyal et al., 2012). Sequencing revealed 
that both isoforms involve exon extension via alternative splicing, producing in frame early stop 
codons for the resultant predicted protein. Specific roles for these two PGC-1α-a variants have 
not been identified.  
Much more is known about NT-PGC-1a, with several studies published on its regulation 
and localization in different tissues since its original identification in mice (Chang et al., 2010; 
Shen et al., 2012; Zhang et al., 2009). NT-PGC-1α was first reported by Zhang and colleagues 
in 2009.Its transcript utilized the same promoter as the canonical isoform, but alternative 3' 
splicing between exons 6 and 7 resulted in a frameshift, introducing a stop codon in the 31 bp 
splicing insert 3 bases after the retained canonical sequence. This resulted in a 270 amino acid 
truncated form of PGC-1α-a, which they named NT-PGC-1α (Novel Truncated).  This truncated 
version retains the activation domain and half of the repression domain (see Fig. 1-2). These 
remaining domains retain 2 out of 3 LXXLL motifs, 2 out of 3 p38 MAPK phosphorylation sites, 1 
AMPK phosphorylation site, and 5 acetylation / deacetylation sites (see table 1-1). It is missing 
all other post-translational modification sites, NLSs, and RNA processing domains. Despite this 
truncation, they found that endogenous levels of this transcript were present at higher levels 
than PGC-1α-a by 1.5 fold. They also found readily detectable levels of NT-PGC-1α protein in 
several tissues (adipose - BAT and WAT, liver, brain, heart, spleen, skeletal muscle, and 
kidney) from mice, rats, and humans. Protein levels of NT-PGC-1α were highest in brain, but 
also detected in mouse BAT, brain, kidney and human heart between 35-38 kDa (predicted 30 
kDa; PGC-1α-a predicted: 93 kDa, observed: 113 kDa). They also found that, as expected since 
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no NLSs were retained, NT-PGC-1α localized to the cytoplasm in mouse adipocytes; however, 
a small proportion of the exogenous NT-PGC-1α (~10%) is localized to the nucleus. This 
percentage increased to 20% upon activation by cAMP but not p38MAPK. Activation of PKA by 
cAMP also increased transcriptional activity of PPARγ, PPARα, and recruitment of NT-PGC-1α 
to associated transcriptional complexes. In a follow-up study (Chang et al., 2010), it was found 
that NT-PGC-1α was regulated by PKA and its interaction with CRM1, a nuclear exportin. This 
exportin also interacts with PGC-1α-a, however, the multiple NLSs present override the CRM1 
induced export from the nucleus to the cytoplasm. PKA functions to inhibit CRM1 by 
phosphorylating NT-PGC-1α at 3 amino acids leading to a retainment of NT-PGC-1α in the 
nucleus, raising its effective concentration. Inhibition of CRM1 resulted in slow increase in 
effective nuclear concentration, therefore nuclear export of NT-PGC-1α must also be taking 
place by CRM1 independent mechanisms as well. Lastly, Shen and colleagues wanted to 
identify the subcellular localization of NT-PGC-1α. Using NT-FLAG NT-PGC-1α in skeletal 
muscle fibers, they found that NT-PGC-1α is localized to the myoplasm.  
            Similar proteins to NT-PGC-1α and PGC-1α ex1-3ext have been predicted, with only a 
few amino acids different at the N-terminus (Ruas et al., 2012; Lochmann, T. and Hedrick, S., 
unpublished findings).  The reason that there would be two extremely similar versions of these 
isoforms is not yet known, and would be a mystery that this project can contribute to solving. 
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Fig. 1-5: PGC-1α isoforms. Exon maps of all PGC-1α isoforms to date. Boxes represent exons. Like colors 
represent the same exon, Lines represent introns. See Table 1-2 for more detailed information about each 
isoform. 
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*All refers to all tissues mentioned in this table. 
**Putative migration size 
	  
PGC-­‐1a	  
isoform	  
category	  
Isoform	  name	  
Human?	  
(Y	  or	  N)	  
Tissues	  
Predicted	  
MW	  
Migrating	  
MW	  
Primary	  
Reference	  
a	  variants	  
PGC-­‐1α-­‐a	   Y	   All*	   91	  kDa	  
90-­‐115	  
kDa	  
Puigserver	  et	  al.,	  
1998	  
NT-­‐PGC-­‐1α	   Y	  
heart,	  	  brain,	  
kidney,	  BAT	  
30	  kDa	   35-­‐38	  kDa	   Zhang	  et	  al.,	  2009	  
PGC-­‐1a	  ex1-­‐3ext	   Y	   brain	   16	  kDa	   TBD	   Soyal	  et	  al.,	  2012	  
PGC-­‐1a	  ex1-­‐8a	   Y	   brain	   33	  kDa	   TBD	   Soyal	  et	  al.,	  2012	  
b	  variants	  
PGC-­‐1α-­‐b	   Y	  
SM,	  heart,	  
brain	  
92	  kDa	   TBD	   Muira	  et	  al.,	  2008	  
PGC-­‐1α-­‐2	   N	  
brain,	  BAT,	  
kidney,	  
heart,	  SM	  
42	  kDa	   50	  kDa	   Ruas	  et	  al.,	  2012	  
PGC-­‐1α-­‐4	   N	  
brain,	  BAT,	  
kidney,	  
heart,	  SM	  
29	  kDa	   ~40	  kDa	   Ruas	  et	  al.,	  2012	  
PGC-­‐1α-­‐b-­‐3T1	   Y	   HSM,	  brain	   15	  kDa	   17	  kDa*	  
Current	  thesis	  
data	  
PGC-­‐1α-­‐b?	   Y	   HSM,	  brain	   TBD	  
TBD	  (90	  
kDa)	  
Current	  thesis	  
data	  
c	  variants	  
PGC-­‐1α-­‐c	   N	  
SM,	  heart,	  
brain	  
92	  kDa	   TBD	   Miura	  et	  al.,	  2008	  
PGC-­‐1α-­‐3	   N	  
brain,	  BAT,	  
kidney,	  
heart,	  SM	  
41	  kDa	   50	  kDa	   Ruas	  et	  al.,	  2012	  
NT-­‐
truncated	  
L-­‐PGC-­‐1α	   Y	   liver	   74	  kDa	   77	  kDa	   Felder	  et	  al.,	  2012	  
NT-­‐
extended	  
B5-­‐PGC-­‐1α	   Y	   brain	   92	  kDa	   TBD	   Soyal	  et	  al.,	  2012	  
B5-­‐PGC-­‐1α-­‐3ext	   Y	   brain	   17	  kDa	   TBD	   Soyal	  et	  al.,	  2012	  
Table 1-2. PGC-1α isoforms	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PGC-1α-b variants: Three isoform b variants are known. In the literature these are known as 
PGC-1α-b, PGC-1α-2, and PGC-1α4 (Miura et al., 2008; Ruas et al., 2012). PGC-1α-b was the 
first identified novel isoform of PGC-1α, present in mouse skeletal muscle, BAT, and liver by 
Miura and colleagues in 2008. They found a full-length transcript, compared with that of PGC-
1α-a that was under the control of an upstream promoter. This promoter utilizes an alternative 
exon 1, which they denoted as exon 1b. Alternative splicing allowed exon 1b to be spliced to 
canonical exon 2, and thus the remainder of the transcript is identical to that of PGC-1α. The 
CDS – ending in exon 13 – only differs from PGC-1α-a by 12 amino acids at the NT, as it is 
coded by the only differing region in the transcript: exon 1b. It was found that although mRNA 
content was only 10% of that of PGC-1α-a, this isoform was greatly upregulated in skeletal 
muscle in response to endurance exercise, while PGC-1α-a remained unchanged (Miura et al., 
2008). This was thought to be caused by β-2 adrenergic receptor activation, because 
clenbuterol treatment of inactive mice caused similar fold increases on isoform b expression 
only in skeletal muscle, while leaving canonical levels unaffected. Transcript levels of isoform b 
also changed in BAT in response to cold exposure while canonical PGC-1α-a remains the 
same. In liver, however, fasting produced changes in canonical PGC-1α, but not isoform b 
transcript expression. Exogenous overexpression of PGC-1α-b in both HEK293 cells and mice 
resulted in the upregulation of nuclear encoded mitochondrial genes necessary for 
mitochondrial biogenesis and fatty acid oxidation (mtTFA, COX2, COX4, ERRα, MCAD) which 
increased upon coexpression of PPARs (Miura et al., 2008).  These initial isoform b findings 
showed that this isoform was functional as a transcriptional coactivator both in vitro and in vivo, 
though by forced overexpression. This isoform has low basal levels under normal physiological 
conditions (varying from 1 to 10% of total PGC-1α mRNA detected in various mouse tissues). 
Under stress, however, this isoform's level increased dramatically (28-350 fold) in a tissue-
specific manner, accounting for a majority of total PGC-1α increase under these conditions 
 38 
 
(Miura et al., 2008). This was one of the first insights to being able to control PGC-1α levels in a 
spatio-temporal manner for translational applications. 
            In response to this publication, several studies have been done regarding the 
transcriptional regulation of this isoform in both mice and humans, more specifically in skeletal 
muscle. Yoshioka and colleagues were the first to identify PGC-1α-b transcript in human 
skeletal muscle (Yoshioka et al., 2009). They described a functional E-box as well as a putative 
CRE site in the promoter region of the isoform b transcript in human skeletal muscle.  They 
demonstrated in vitro that both of these sites are able to directly bind MyoD / MRF4 and CREB, 
respectively, resulting in promoter activation and increase in mRNA levels of PGC-1α-b. They 
also showed that the recruitment of CREB to the CRE site occurs in several ways via calcium 
induced signaling in response to exercise to induce PGC-1α-b expression. These include 
CamKIV and CnA, which activate CREB directly via serine phosphorylation or indirectly via 
activation and nuclear import of CREB coactivator TORC, respectively. Alternatively, exercise 
induced cAMP or p38 MAPK signaling can also recruit CREB.  Forskolin, which increases cAMP 
levels, causes PKA activation which can phosphorylate and thus activate CREB. Considering β-
2 adrenergic receptor stimulation upon catecholamine release upon exercise would also 
increase cAMP release, this model works nicely with the clenbuterol activation of this isoform 
shown by Miura and colleagues in mice. They also showed that MKK6, an activator of p38 
MAPK signaling, can also lead to CREB phosphorylation and activation (Yoshioka et al., 2009). 
P38 MAPK and CnA involvement in PGC-1α-b activation has come into question; however, 
Norrbom and colleagues suggested that there is a role for AMPK instead, in that isoform b is 
stimulated via AICAR and norepinephrine (Norrbom et al., 2011). This finding also aligns with 
the model of β-2 adrenergic receptor activation in response to exercise (Miura et al., 2008). 
These findings reveal several ways to target PGC-1α in a tissue-specific manner.   
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            Two new PGC-1α isoforms were found by Ruas and colleagues recently (Ruas et al., 
2012). These are somewhat similar to some previously described isoforms found in mice and 
humans. These isoforms are called PGC-1α-2 and PGC-1α-4. PGC-1α-2 is an isoform b (PGC-
1α-b: Miura et al., 2008) variant. It begins at the same exon 1b (called exon 1''' in Ruas paper) 
and instead of extending down to exon 13 with the same splicing as canonical PGC-1α, 
contains partial sequence conservation due to alternative splicing of only exons 3, 7, and 8 
(excluding all other exons downstream of exon 3 from canonical PGC-1α). This alternative 
splicing does not result in the formation of an early stop codon, however, and ends in a newly 
described exon 14. This would results in a predicted protein of 379 amino acids (41.9 kDa).  
From gene expression array studies, it was determined that this isoform affected 110 genes, 
some differing from canonical PGC-1α. No functional studies have been reported on this 
isoform as of yet. 
            The second isoform they described, PGC-1α-4, is very similar to NT-PGC-1α. It contains 
the same splicing variation between exons 6 and 7, resulting in the formation of an early stop 
codon, but instead of the primary exon being exon 1a, it is exon 1b; therefore making this an 
isoform b variant under the control of the same alternate promoter (Ruas et al., 2012). This 
results in a predicted protein of 266 amino acids (29.1 kDa).  In a gene expression array, PGC-
1α-4 held 98 out of 519 genes affected in common with PGC-1α-a. It did not seem to affect 
several classic target genes of PGC-1α-a, including several genes involved with oxidative 
phosphorylation. These include CytC, CoxVb, Glut4, PDGFb, and MCAD. Despite this 
difference in regulation, presumably due to being under the control of an alternate promoter 
region as well as having vastly different C-termini, this isoform was found to be similar to PGC-
1α-a in most ways. It retained transcriptional coactivator function, however, no longer could 
coactivate ERRα or ERRγ, which could explain changes in classic target genes. It also was not 
upregulated in skeletal muscle (in vivo human and murine biopsied muscle) in response to 
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endurance exercise, unlike PGC-1α-a. PGC-1α-4 was upregulated in response to resistance 
exercise, however. Also differing from PGC-1α-a, PGC-1α-4 upregulation in response to 
resistance training also results in increased IGF1 levels and decreased myostatin levels. IGF1 is 
an activator for muscle fiber hypertrophy and myostatin is a negative regulator of muscle size 
and strength (Ruas et al., 2012). These differences in function are the first described for a PGC-
1α isoform. This information provides more evidence for the therapeutic potential of PGC-1α. 
For this particular isoform alone, there is the possibility for future translational developments to 
improve muscle-wasting in various diseases, including muscular dystrophies, 
neurodegenerative disorders, aging, and cancer cachexia. For this reason, determining the 
functional and tissue differences among the remaining PGC-1α isoforms is extremely important.                    
PGC-1α-c variants:  PGC-1α-c is very similar to PGC-1α-b, with a few known exceptions to 
date.  Both utilize the same alternative exon 1b and promoter, splicing to exon 2 and continuing 
the splicing of canonical PGC-1α down to exon 13. PGC-1α-c, though, is spliced to exon 2 using 
a different slice donor in exon 1b than PGC-1α-b, resulting in a slightly shorter CDS (Miura et 
al., 2008). In response to exercise, similar to PGC-1α-b, PGC-1α -c expression was induced 41 
fold in skeletal muscle. Unlike PGC-1α-b, however, PGC-1α-c was not induced in response to 
cold exposure in BAT. Neither were induced in fasting conditions in the liver; only PGC-1α-a 
(Miura et al., 2008). Only noted in mice thus far, and although the TSS is conserved in humans, 
the mRNA transcript for isoform c was not found in human skeletal muscle in 5' RLM-RACE 
experiments in our laboratory (Lochmann, T. unpublished observation). Considering these 
isoforms share the same promoter, it is unclear how they could be targeted differently. For 
example, isoform b but not isoform c is upregulated in BAT of mice in response to cold 
exposure. The alternative promoter which produces isoform b and c transcripts contains a 
putative CRE site and E-box. These two features are common in muscle-specific COX genes, 
depending upon E-box consensus elements for their tissue-specific expression (Moreadith, 
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1995). This is interesting considering that both these isoforms are found to be upregulated in 
immediate response to short bouts of exercise in skeletal muscle of both mice and humans 
(Miura et al., 2008; Yoshioka et al., 2009; Norrbom et al., 2011). No further investigations into 
isoform c regulation or function have been published to date. 
            Ruas and colleagues found an isoform c transcript variant, occurring as the result of 
alternative splicing which they called PGC-1α-3. The TSS is shared with that of PGC-1α-c, and 
the rest of the transcript follows the same alternative splicing pattern as that of PGC-1α-2, 
another isoform variant they described in the same publication (Ruas et al., 2012).   It would 
result in a protein of 370 amino acids (41.0 kDa). A gene expression array showed that its 
upregulation affects 69 genes, some of which differ from that of canonical PGC-1α.  No further 
investigations into the regulation or function of this isoform c variant have been published to 
date.       
            Interestingly, even though isoform b and c transcripts increase together in response to 
stress in tissues tested, this increase did not fully account for the amount of total PGC-1α in 
qPCR studies. This also applies in human tissues tested in our lab (Lochmann, T.; Hedrick, S.; 
Thomas, R. unpublished observations). This leads us to believe that these are not the only 
PGC-1α isoforms that exist. Since the reverse primers used in the qRT-PCR experiments lie in 
exons 2 and 3, the remaining isoforms must have alternative splicing or novel exons and 
promoters upstream or downstream of these exons. 
NT-truncated: The NT-truncated category describes the PGC-1α isoforms whose promoter lies 
downstream of that of canonical PGC-1α. One such isoform, called L-PGC-1α, was described in 
human liver (Felder et al., 2011). It was found via 5' RLM RACE of human liver and identified via 
amplicon sequencing. It is transcribed off a novel alternative PGC-1α promoter located within 
the reference intron following exon 2, which continues on to exon 3 with the reminder of the 
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transcript identical to canonical PGC-1α. This transcript is thought to be human specific, as it 
was not detected within a panel of other mammalian tissues. It is also not found in other human 
tissues investigated (kidney, brain, skeletal muscle). Thus, this is believed to be an isoform 
which evolved specifically for function in human liver.   
            The resultant 77 kDa protein, found endogenously translated in human liver and HEPG2 
cells via immunoblot, is missing several functional domains compared to PGC-1α-a. These 
omissions include the SRC-1 and CREB-binding protein recruitment regions of the activation 
domain, the first LXXLL binding motif, an NES, and a GCN5 binding site. Lacking SRC-1 and 
CBP sites is especially interesting because these are necessary for recruiting and binding and 
PGC-1α chromatin remodeling partners. The inability for this isoform to indirectly dock and / or 
modify regions of chromatin and therefore make DNA available for changes in transcription 
could definitely lead to functional differences in comparison to its full-length counterpart. Similar 
to PGC-1α-a, L-PGC-1α was found to localize to the nucleus and is functional there, 
upregulating the same genes as PGC-1α-a in trans-activation studies (Felder et al., 2012).  As 
aforementioned, SIRT1 can deacetylate PGC-1α which specifically decreases the ability for 
PGC-1α-a to upregulate genes involved in gluconeogenesis. The fact that L-PGC-1α lacks this 
site and its liver specificity suggests that it prevents constitutive gluconeogenesis from being 
shut down in humans.    
NT-extended:  The NT-extended category describes the remaining PGC-1α isoforms whose 
promoter lies upstream of that of canonical PGC-1α. Most of these isoforms were described in a 
publication by Soyal et al. in 2012, in which they found promoters 373 and 207 kb upstream of 
the promoter region for canonical PGC-1α in human brain tissue via 5' RLM RACE, and verified 
via long-range PCR followed by sequencing as well as northern blot. These resulted in several 
full length as well as alternatively spliced transcripts. These transcripts code for several potential 
brain-specific full-length and truncated proteins delineated in Table 1-2. Novel exons B4 and B5 
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continue to exon 2 producing two novel 803 and 786 amino acid human PGC-1α isoforms. 
These novel exons B4 and B5 can also be subjected to alternative splicing near exons 3, 7, and 
8. These splicing events result in frameshifts and thus early stop codons, producing truncated 
forms of their full-length counterparts. These isoforms are delineated in Fig. 1-2. 
            In the studies by Soyal et al. (2012), although an immunoblot using an antibody to PGC-
1α resulted in several bands in SH-SY5Y nuclear and cytosolic extracts, it was unclear whether 
any of the bands corresponded to the predicted proteins, as the predicted molecular weights did 
not align, and the size of three of the potential isoforms were very similar to the size of canonical 
PGC-1α (</= 1 kDa difference) which should have also been present in the nuclear extract 
(Soyal et al., 2012). In a recent publication, a protein was found in mitochondrial extracts of 
human brain and SY5Y cells that was ultimately unable to be sequenced to determine its 
identity (Choi et al., 2013). These investigators reported that they believed this transcript to be 
one of the NT-extended isoforms predicted to be a similar molecular weight. This could 
correspond to either B4 or B5 isoforms that are truncated in the coding sequence of exons 7a or 
8a (Soyal et al., 2012). The true identity of the transcript resulting in this mitochondrial isoform is 
unknown. This 35 kDa PGC-1α isoform has been found to associate with PINK1 and VDAC in 
mitochondrial extracts of mouse hippocampal tissue as well as the human SH-SY5Y cell line. Its 
import was believed to be dependent upon VDAC binding shown by VDAC siRNA studies. 
Inside the mouse hippocampal mitochondrion, this 35 kDa form of PGC-1α was found to co-
localize with PTEN-inducible kinase 1 (PINK-1). 35 kDa PGC-1α could potentially be 
phosphorylated by this kinase in order to carry out its signaling inside the mitochondrion. This is 
interesting considering that downregulation of either of these proteins is associated with both 
neurodegenerative disease – for PINK1, Parkinson's Disease in particular – and diabetes. This 
provides insight into a potential direct link of PGC-1α control to mitochondrial function and 
dysfunction.    
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            Choi et al. also reported that their P-120 antibody detected several other bands which 
were not detected upon siRNA knockdown.  These occurred in HEK WCLs at 100, 91, 45, 40, 
and 35 kDa. Other than the canonical form at 91 kDa, and the mitochondrial form at 35 kDa, 
these could be potential undescribed human isoforms transcribed from promoters previously 
mentioned in which transcripts have been detected but no protein described (isoform b, c, NT-
extended promoters). Alternatively, these could be post-translationally modified versions of 
PGC-1α-a or its isoforms. 
            None of the functions of the NT-extended isoforms reported by Soyal et al. have been 
investigated. Clues to their potential roles have been noted, however. In the promoter region lies 
an Ebox, a potential binding site for transcription factors such as USF1 and SREBP-1c. E-boxes 
are glucose response elements that have the ability to bind to transcription factors in the basic 
helix-loop-helix-leucine zipper family. One of these such TFs is USF1 (upstream stimulatory 
factor), which is a mediator of glucose action and fatty acid synthesis. However, there is no 
evidence that changes in levels of glucose directly cause changes in transcriptional activity of 
USF1. SREBP-1c, however, has now been demonstrated as the TF that is directly 
downregulated and upregulated by increases in glucagon and insulin, respectively. SREBP-1c 
is thus responsible for the transcriptional regulation of glucose induced genes, such as those 
regulated by USF1 (Foretz et al., 1999). SREBP-1c can also bind to E-boxes and thus may 
work together with USF1 in glucose sensing and response as well as fatty acid production 
(Tontonoz et al., 1993). It is interesting that these E-boxes have been found both in the 
promoters of PGC-1α-b and the NT-extended brain-specific isoforms (Yoshioka et al., 2009; 
Soyal et al., 2012). These may contribute to the role of PGC-1α in glucose sensing, uptake, and 
fatty acid metabolism identified in neurons in genome-wide expression studies (GWES) of early 
asymptomatic Parkinson's Disease (Zheng et al., 2011). Also similar to isoform b, these NT-
extended isoforms have the potential to be epigenetically regulated. Their promoter regions lie 
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within a large CpG island which was found in chIP studies to have a brain-specific neuron 
H3K4Me3 histone modification (Soyal et al., 2012). These regulation sites suggest a spatio-
temporal regulation of these novel PGC-1α isoforms.      
VI. Project overview 
Since the first PGC-1α isoforms were identified in 2008 by Miura and colleagues in mice, 
several others have been published. For some, only a mature transcript have been identified. 
For others, the encoded protein has been detected via western blot deduced from predicted 
molecular mass. None have been positively confirmed to correspond to a particular transcript. 
Most of these isoforms have been identified in rodents, but some have also been described in 
human tissues. Some are similar in length to canonical PGC-1α, and some are truncated, 
missing important functional domains compared to canonical PGC-1α that could alter its 
comparative function. Most of these isoforms are also regulated in a tissue-specific manner. It is 
necessary to find and characterize all isoforms of PGC-1α to fully understand ways of 
modulating PGC-1α in a tissue-specific and thus pharmacologically targetable and disease-
relevant manner.   
            Therefore, the goals of this project were to identify which PGC-1α-b variants exist in 
different human tissues and also which make viable proteins. This is the cornerstone to 
determining the functions of those proteins and discerning if those functions are unique to 
particular isoforms previously thought to be accomplished by canonical PGC-1α-a.  
We have developed a PGC-1α isoform b specific primary antibody (Genscript). Its 
epitope lies in the coding sequence of exon1b, the only region that differs between full length 
isoform b and canonical PGC-1α. One of the aims of this project is to optimize and characterize 
this new antibody against a recombinant isoform b variant, which we are calling PGC-1α-b 3T1 
(exon 3 truncation 1, Table 1-2), as well as endogenous PGC-1α-b present in whole cell lysates. 
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Once this antibody is characterized, it will open opportunities to probe for PGC-1α -b to 
determine which of its variants exist in different human tissues. If the tissue-specific effects of 
these isoforms – which have already been hinted to in isoform b transcript regulation studies – 
can be fully elucidated, this information can be harnessed to serve as a target for therapeutics, 
including pharmacological intervention. 
 
  
 
 
 
	   	  
 47 
 
 
 
CHAPTER 2  
MATERIALS AND METHODS 
 
 
 
Tissue samples 
Genomic DNA and RNA from prefrontal cortex brain tissue samples from age-matched healthy 
and Parkinson’s disease patients were obtained from the UVA brain bank (Charlottesville, VA), 
with DNA and RNA purified from snap frozen homogenized tissue samples from PFC using 
AllPrep DNA/RNA mini kit using manufacturer’s instructions (Qiagen, Valencia, CA). Six patient 
samples were used total, blinded via patient number (3 healthy, 3 PD) until all results were 
analyzed: 122, 170, 174 (healthy control), 191, 203, 213 (PD).  
qRT-PCR 
RNA from patient brain samples were reverse transcribed (3.5 µg each) using Superscript III 
First-Strand cDNA synthesis kit (Invitrogen, Grand Island, NY) using manufacturer’s instructions 
for random hexamer primed RNA. Primer sets were optimized using human skeletal muscle 
cDNA. Once melting temperatures were optimized, qPCR was performed using DNA Engine 
Plus real-time PCR system (Bio-Rad, Hercules, CA) with the FastStart Universal SYBR Green 
Master kit (Roche, Indianapolis, IN). DNA template (0.1 µg) and 0.2 µM primers were used in 
each reaction in a final volume of 20 µL. The amplification reaction program was set as a total of 
40 cycles of denaturation at 94°C for 45 seconds, annealing at the appropriate temperature 
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(57oC) for each target region for 45 seconds, and extension at 68°C for 45 seconds, with an 
initial denaturation at 94°C for 5 minutes and a final extension at 68°C for 10 minutes along with 
a melt curve analysis step extended to 98oC. Data were analyzed by Opticon Monitor software. 
Relative RNA abundance was determined by normalizing to an average of two mitochondrial 
housekeeping genes, GAPDH and CYC9, which showed the least variance in this particular 
tissue type compared to an array of other housekeeping genes.  
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Bisulphite conversion – PCR amplification  
Genomic DNA (500 ng) from patient prefrontal cortex samples were treated with bisulphite using 
the EZ Gold DNA methylation kit (Zymo Research, Orange, CA) and eluted in 30 µl of HPLC 
grade water. The bisulphite treated DNA was then amplified using 10 primer sets (7 for isoform 
A, 3 for isoform b) containing Cs converted to Ts. Each amplicon was 300-400bp in length 
across a 1 kb span of the upstream promoter region; these primers also contained sample 
specific multiplex identifiers (MIDs ), synthesized by Eurofins MWG Operon (Huntsville, AL). 
These amplicons were generated with Invitrogen Platinum PCR Supermix – high fidelity 
polymerase (Grand Island, NY) (single reaction, 0.5 µL of bisulphite converted template 
(approximately 17.5 ng DNA) and 0.2 µM of forward and reverse primers using BioRad DNA 
Engine thermocycler. All PCR amplifications consisted of a total of 40 cycles of denaturation at 
94°C for 45 seconds, annealing at the appropriate temperature for each target region for 45 
seconds (see primer usage table), and extension at 68°C for 45 seconds, with an initial 
denaturation at 94°C for 5 minutes and a final extension at 68°C for 10 minutes. The amplicons 
were gel purified from a 3% Nu-Sieve agarose gel with 1xTBE, run at 80V for 1 hr. Bands were 
excised and DNA extracted using EZNA Gel Extraction Kit (Omega Bio-tek, Norcross, GA), 
following manufacturer’s instructions except eluted twice with15uL elution buffer, with a 10min, 
RT incubation for each elution. All amplicons for isoform A and B, each with different MIDs for 
each sample (60 amplicons total) were combined in equimolar ratios and sent to Eurofins MWG 
operon for 454 high throughput bisulphite sequencing and subsequent sample separation via 
MIDs. Methylation levels (% protected Cs) were assessed at the single CpG dinucleotide level 
using multiple sequence alignment compared to unconverted DNA with an extended and 
improved version of BiQ Analyzer (Bock et al., 2005), the BiQ Analyzer-HT software (Lutsik et 
al. 2011). Percent conversion exceeded 99%. 
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Subcloning and Gateway Cloning  
(1) PGC1a Mammalian expression vectors 
HSM PGC-1a-b-3T1 to PCR 4 TOPO: PGC-1α-b-3T1 was amplified from human skeletal 
muscle total RNA (Ambion) using primers which added KpnI and NotI restriction sites on the 5' 
and 3' ends, respectively (see primer usage table; Fig. 3A). The amplicon was then purified 
using QiaQuick PCR purification kit (Qiagen, Valencia, CA), subsequently TOPO cloned using 
the PCR 4 TOPO – TA cloning kit (Invitrogen, Carlsbad, CA), and then transformed into TOP10 
cells according to manufacturer's instructions (Life Technologies, Grand Island, NY). The 
transformation was plated onto 50 µg/mL Carbenicillin LB agar at RT for 30 hours. Colonies 
were then picked, diluted in 20 µL SOC, PCR screened with the same primers used for initial 
amplification, and simultaneously streaked onto a fresh 50 µg/mL Carbenicillin LB agar plate to 
obtain pure colonies. Pure colonies from several positive clones containing the correct size 
insert were grown in 5mL 2xYT cultures in 15-mL polypropylene snap-cap culture tubes for 6-8 
hours under antibiotic selection, with 500 µL made into 10% glycerol stocks at O.D. 0.5-0.6, and 
spun down for 20 min. at 4°C between O.D. 1.0-1.5. DNA was purified from these cells using 
the EZNA Plasmid Mini Kit I (Omega Bio-tek, Norcross, GA) following manufacturer’s 
instructions with the exception of the elution step, which was carried out twice using 15uL of 
elution buffer following a 10 minute incubation at RT. Mini-prepped DNA was then restriction 
digested with XhoI to ensure no rearrangement occurred during culture growth. Three correctly 
digested clones from each construct were then sequenced (Operon) to ensure no mutations 
were introduced during PCR using T7 and M13R standard primers. Clones containing correct, 
high quality sequence were then midi-prepped (Purelink HiPure Plasmid DNA purification Kit: 
Invitrogen, Carlsbad, CA), restriction digest verified (BamHI, EcoRI, XhoI FastDigest restriction 
enzymes: Thermo Scientific, Pittsburgh, PA), and subsequently quantified via densitometry 
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using Li-COR's DNA gel analysis software (LI-COR biosciences, Lincoln, NE) with the 1 kb and 
100 bp mass ladders (New England Biolabs, Ipswich, MA).  
PCR 4 TOPO to pENTR1a: 10 µg of PGC-1a-b-3T1 TOPO plasmid as well as the pENTR1a 
dual selection Gateway vector (Life Technologies, Grand Island, NY) were then restriction 
digested with fast digest enzymes (Thermo Scientific, Pittsburgh, PA) according to 
manufacturer's protocol using the restriction sites initially introduced for subcloning. The entire 
digest reaction was run on a 1% TAE agarose gel, and the correct bands corresponding to 
insert and empty vector were excised. The DNA was then gel extracted using EZNA Gel 
Extraction Kit (Omega Bio-tek, Norcross, GA). Ligation was carried out using Roche Rapid DNA 
Ligation Kit (Roche, Indianapolis, IN) with a 3:1 molar excess of insert to vector using 100 ng of 
vector DNA. 5 µL of the ligation reaction was used to transfect 100 µL of SURE2 competent 
cells, using manufacturer's instructions (Agilent, Santa Clara, CA), and 50 µL of the cell 
suspension was plated on LB agar with 50 µg / mL Carbenicillin for overnight incubation at 
37oC. Clones were screened by colony-PCR, mini-prepped and further validated by restriction 
digest and sequencing.  
pENTR1a / pDONR201 to pDEST40 and pDEST 26 CT FLAG: Previously in our lab, PGC-1α-a 
in pENTR22.1 was obtained from DNASU plasmid repository and subcloned via BP gateway 
reaction into pDONR201 with BP clonase following manufacturer’s instructions (Lochmann, T.). 
I then subcloned PGC-1α-a into pDEST26 CT FLAG (modified Life Technologies vector kindly 
provided by Dr. Rita Shiang) and PGC-1α-b-3T1 into pDEST40 via LR clonase reaction 
following manufacturer’s instructions (Life Technologies, Grand Island, NY). 2 µL of the LR 
clonase reaction was then used for transformation into 50 µL of SURE2 cells. 50 µL of the 
transformation reaction was plated onto 50 µg / mL Carbenicillin LB agar for 37°C incubation 
overnight. Clones were screened once again as described above and midi-prepped.  Both 
pDEST constructs were sequenced with T7 and BGHrev as well as interior forward and reverse 
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primers to cover the entire 2.5 kb isoform A construct (pGC1a IsoA inner Fw, Rv 5’ – 
GCAAAAGCCACAAAGACGTCC – 3’, 5’ – CTACTGCCTGGAGACCTTGATC – 3’).            
(2) PGC1a-3T1 Bacterial expression vector 
DNA was amplified from human skeletal muscle cDNA using primers which added on KpnI and 
NotI restriction sites to the 5' and 3' end of the amplicon, respectively (Table 2-1). The PCR 
product (4 reactions worth) was combined and subsequently cleaned of excess primers using 
the QiaQuick PCR Purification Kit per manufacturer's instructions (Qiagen, Valencia, CA) and 
reduced to a 30 µL total volume. 10 ug of this PCR product and the vector (pET41a) were then 
restriction digested with BamHI and XhoI Fast Digest enzymes per the manufacturer's protocol 
(Thermo Scientific, Pittsburgh, PA). Subsequent DNA gel, gel extraction, ligation, 
transformation, and colony / clone screening were carried out as stated in mammalian vector 
preparation portion of the methods. Exceptions include that the ligation reaction was 
transformed into DH5alpha subcloning efficiency competent cells (Life Technologies, Grand 
Island, NY) with 50 ug / mL Kanamycin selection, no midi-prepping was necessary for this 
construct, and that it was subsequently transformed into BL21(DE3) competent cells for 
bacterial expression of the recombinant protein. Recombinant GST/PGC-1α-b-3T1 fusion 
contains an NT GST and 6x His tag fused to PGC-1α isoform b 3T1, followed by a CT 6x His 
tag to aid in protein purification (see Fig. 3-3C for vector schematic; Fig. 2-2 for Plasmid and 
amino acids sequence).  
 
Recombinant bacterial protein expression and purification 
The colony used for this bacterial protein expression was restriction digest checked with the 
enzymes used to clone in the construct (KpnI and NotI) as well as one enzyme interior to the 
construct (NheI) prior to protein expression. Conditions for recombinant protein expression were 
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optimized to growing a single pure colony in 6 mL LB until an OD of 0.5 was reached. The 
cultures were then kept at 4°C, overnight and spun down at 8,000 rpm for 5 min. at 4°C, and the 
pellet gently resuspended in 2 mL of fresh LB. This was added to 48 mL of 50 ug / mL 
supplemented LB and incubated at 37°C until an OD of 6.0 was reached. At this point, a 3-2 mL 
aliquots were pelleted and frozen for later analysis of uninduced bacterial lysate and IPTG was 
added to a final concentration of 1 mM. The induced culture was incubated for 4 hours at 37°C, 
then the OD was taken and 2-1mL aliquots were pelleted and frozen for later analysis. Cells 
were then harvested at 4000 rpm for 30min. at 4°C. After the supernatant was removed, the 
pellet was frozen prior to lysis for higher protein yields. The pellet was resuspended in 2 mL 
BugBuster protein extraction reagent (Novagen; Merck KGaA, Darmstadt, Germany) plus 1x 
Roche “complete” protease inhibitor cocktail, following manufacturer's protocol. The lysed cells 
were then bath sonicated for 10 minutes on high setting, 30s on/off. The lysate was then batch 
purified using 0.5 mL resin bed volume of glutathione agarose according to manufacturer's 
instructions (Pierce, Rockford, IL). Elutions were collected as 5-0.5 mL fractions and stored at 
4°C. 
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A 
5’- TGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTT 
TTGGAATATCTTGAAGAAAAATATGAAGAGCATTTGTATGAGCGCGATGAAGGTGATAAATG
GCGAAACAAAAAGTTTGAATTGGGTTTGGAGTTTCCCAATCTTCCTTATTATATTGATGGTG
ATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCACAACATGTTG
GGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTGGATATTA
GATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACTCTCAAAGTTGATTTTCTTA
GCAAGCTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAAACATATTTAAAT
GGTGATCATGTAACCCATCCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATACAT
GGACCCAATGTGCCTGGATGCGTTCCCAAAATTAGTTTGTTTTAAAAAACGTATTGAAGCTA
TCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCATGGCCTTTGCAGGGCTG
GCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGATggttcaactagtggttctggtcatcac
catcaccatcactccgcgggtctggtgccacgcggtagtactgcaattggtatgaaagaaaccgctgctgctaaattcgaacgccagc
acatggacagcccagatctgggtaccggtggtggctccggtgatgacgacgacaagagtcccatgggatatcggggatccACAC
ACATGTTGGGGTTATCATCTATGGATTCAATTTTGAAATGTGCTGCTCTGGTTGGTGAAGAC
CAGCCTCTTTGCCCAGATCTTCCTGAACTTGATCTTTCTGAACTAGATGTGAACGACTTGGA
TACAGACAGCTTTCTGGGTGGACTCAAGTGGTGCAGTGACCAATCAGAAATAATATCCAAT
CAGTACAACAATGAGCCTTCAAACATATTTGAGAAGATAGATGAAGAGAATGGGGCAAACT
TGCTAGCAGTCCTCACAGAGACACTAGACAGTCTCCCTGTGGATGAAGACGGATTGCCCT
CATTTGATGCGCTGACAGATGGAGACGTGACCACTGACAATGAGGCTAGTCCTTCCTCCAT
GCCTGACGGCACCCCTCCACCCCAGGAGGCAGAAGAGCCGTCTCTAGTAAGAACCCTTCC
TACTGTTctcgagcaccaccaccaccaccaccaccactaa – 3’ 
	  
B 
 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVK
LTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEML
KMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLK
SSKYIAWPLQGWQATFGGGDHPPKSDGSTSGSGHHHHHHSAGLVPRGSTAIGMKETAAAKF
ERQHMDSPDLGTGGGSGDDDDKSPMGYRGSTHMLGLSSMDSILKCAALVGEDQPLCPDLPE
LDLSELDVNDLDTDSFLGGLKWCSDQSEIISNQYNNEPSNIFEKIDEENGANLLAVLTETLDSLP
VDEDGLPSFDALTDGDVTTDNEASPSSMPDGTPPPQEAEEPSLVRTLPTVLEHHHHHHHH* 
	  
	  	  	  	  	  	  	  	  	  	  	  	  
Fig. 2-2: Coding region for recombinant GST/PGC-1a-b-3T1 fusion. (A) DNA sequence of the coding region for 
GST/PGC-1a-b-3T1 in pET41a. (B) Resultant amino acid sequence translated from part A. Red = pgc1a isoform b 
3T1; Green = His tags; Blue = GST; Red = epitope. 
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Generation and validation of expression plasmids for PGC1a isoforms 
Midi-prepped DNA (Purelink HiPure Plasmid DNA purification Kit: Invitrogen, Carlsbad, CA) was 
restriction digest verified (FastDigest restriction enzymes: Thermo Scientific, Pittsburgh, PA) 
and subsequently quantified for DNA concentration via densitometry using Li-COR's gel 
analysis software (LI-COR biosciences, Lincoln, NE) and comparison to the 1 kb and 100 bp 
mass ladders (New England Biolabs, Ipswich, MA). This endotoxin-free DNA was then 
transfected into HEK293 cells at 80% confluency  in 6-well plates (~960,000 cells / 
well)(American Type Culture Collection, Manassas, VA) using Polyjet DNA in vitro Transfection 
Reagent, according to the manufacturer's protocol (SignaGen Laboratories, Rockville, MD) with 
the exception that a 3:2 polyjet (µL)/DNA (µg) ratio was used with 2ug of DNA per dish An 
expression vector encoding eGFP (pmaxGFP: Lonza, Basel, Switzerland) was used to 
determine transfection efficiency.  Cells were imaged for GFP using a fluorescent microscope at 
24 and 48 hrs, and harvested 48 hours post transfection. Cells were washed, scraped and 
pelleted in 1x PBS, pH 7.4. Cells were resuspended in SDS lysis buffer [(62.5 mM Tris pH 6.8, 
5% glycerol, 2% SDS, 5% beta-mercaptoethanol, and 1x EDTA-free “cOmplete” protease 
inhibitor cocktail (Roche, Indianapolis, IN)] at a volume 5x the pellet weight and lysis was carried 
out by bath sonication for 7 min. total, high setting, 30s on/off (Bioruptor: Diagenode, Denville, 
NJ).   
 
SDS-PAGE and Immunoblotting  
Per lane on the gel, each sample contained 50 to 100 ug of whole cell lysate (WCL) or 0.001 ng 
to 10 µg of recombinant protein (see figure legends for details). All protein samples were mixed 
with an equal volume of 2x Laemmli sample buffer (Bio-Rad, Hercules, CA) and brought up to a 
final volume of 45 µL with SDS lysis buffer. Proteins were resolved on 4–15% gradient 
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SDS/PAGE gels (Mini-protean GTX: Bio-Rad, Hercules, CA) at 90 volts. For protein 
visualization, gels were stained with Coomassie brilliant blue overnight and destained with (v/v) 
30% methanol, 10% glacial acetic acid in ultrapure water. For western blotting, resolved 
proteins were transferred to a 0.45 micron PVDF  
 
 
 
 
 
 
Table 2-2: Antibody usage 
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Fig.	  2-­‐2:	  Schematic	  of	  subcloning	  procedure	  of	  PGC-­‐1a-­‐b-­‐3T1	  into	  pDEST40.	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membrane	  using	  a	  wet	  transfer	  apparatus	  for	  1	  hour	  at	  100	  volts	  in	  cold	  1x	  transfer	  buffer	  (25	  mM	  Tris,	  
192	  mM	  glycine,	  10%	  methanol,	  0.1%	  SDS,	  pH	  8.3).	  Membrane	  was	  then	  blocked	  in	  StartingBlock	  T20	  
(Thermo	  Scientific,	  Pittsburgh,	  PA)	  at	  4°C,	  overnight	  with	  gentle	  rocking,	  followed	  by	  a	  1	  hr	  incubation	  at	  
room	  temperature	  with	  primary	  antibody	  with	  gentle	  rocking,	  3	  x	  10	  minute	  washes	  with	  TBS-­‐T	  at	  room	  
temperature	  with	  vigorous	  shaking,	  1	  hr	  incubation	  at	  room	  temperature	  with	  an	  HRP-­‐conjugated	  
secondary	  antibody	  with	  gentle	  rocking,	  followed	  by	  another	  series	  of	  3	  x10	  minute	  washes.	  The	  
samples	  were	  then	  incubated	  for	  5	  min.	  with	  Supersignal	  West	  Dura	  extended	  duration	  
chemiluminescent	  substrate	  (Pierce,	  Rockford,	  IL),	  exposed	  and	  developed	  on	  X-­‐ray	  film.	  Where	  noted,	  
5%	  Nonfat	  dry	  milk	  (NFDM)	  in	  TBS-­‐T	  was	  used	  as	  starting	  block	  with	  1	  hr	  RT	  incubation	  followed	  by	  
overnight	  primary	  incubation	  (see	  figure	  legends).	  The	  primary	  and	  secondary	  antibodies	  used,	  their	  
concentrations,	  %	  ECL	  reagent,	  and	  manufacturers	  are	  listed	  in	  table	  2-­‐2.	  	  
Trypsin	  digest	  and	  Mass	  Spectrometry	  	  
Gels	  were	  stained	  with	  Coomassie	  to	  visualize	  protein	  bands.	  The	  gel	  bands	  were	  subsequently	  cut	  from	  
the	  gel	  and	  destained.	  	  The	  proteins	  were	  reduced,	  alkylated	  and	  digested	  with	  trypsin	  in	  the	  gel.	  	  The	  
peptides	  formed	  in	  the	  digestion	  were	  extracted,	  concentrated,	  and	  characterized	  by	  LC-­‐tandem	  mass	  
spectrometry	  on	  a	  Thermo	  LCQ	  DECA-­‐XP	  MAX	  	  ion	  trap	  (Thermo,	  San	  Jose,	  CA)	  upon	  elution	  from	  a	  
reverse-­‐phase	  phenyl	  resin	  (YMC,	  Kyoto,	  Japan)	  capillary	  column.	  	  The	  mass	  spectrometer	  was	  operated	  
in	  the	  data	  dependent	  mode	  throughout	  the	  HPLC	  gradient	  with	  an	  acquisition	  duty	  cycle	  consisting	  of	  
an	  initial	  MS1	  scan	  with	  a	  mass	  range	  of	  300-­‐1200	  m/z	  followed	  by	  an	  MS2	  acquisition	  of	  the	  5	  most	  
abundant	  ions.	  	  	  	  The	  MS2	  data	  was	  searched	  with	  SEQUEST	  as	  a	  tryptic	  digest	  against	  a	  composite	  
database	  containing	  the	  PGC-­‐1α	  construct.	  	  The	  carbamidomethylation	  of	  cysteine	  (+57	  Da)	  and	  
oxidation	  of	  methionine	  (+16	  Da)	  were	  treated	  as	  variable	  modifications.	  	  The	  tryptic	  search	  results	  for	  
each	  data	  file	  were	  filtered	  by	  xcoor	  for	  (+1,	  +2,	  +3)	  of	  (1.5,2.0,2.5).	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Peptide	  Competition	  Assay	  
	  A	  peptide	  competition	  assay	  (PCA)	  was	  used	  to	  verify	  the	  binding	  specificity	  of	  the	  PGC-­‐1α-­‐b	  specific	  
primary	  antibody,	  which	  was	  affinity	  purified	  and	  produced	  in	  rabbits	  by	  KLH-­‐conjugation.	  The	  molar	  
excess	  factor,	  or	  moles	  of	  blocking	  peptide	  per	  mole	  of	  antibody	  used,	  was	  determined	  via	  titration	  of	  
200-­‐20,000	  molar	  excess	  of	  peptide	  to	  antibody	  against	  10	  ng	  of	  recombinant	  GST/PGC-­‐1α-­‐b-­‐3T1	  fusion	  
protein.	  Immunizing	  peptide	  for	  the	  isoform	  b	  specific	  antibody	  was	  prepared	  at	  1 μg/μL	  in	  pH	  5.5	  PBS	  
to	  prevent	  disulfide	  bond	  formation.	  Primary	  antibody	  was	  blocked	  by	  combining	  0,	  200,	  2000,	  5000,	  
10,000,	  or	  20,000	  molar	  excess	  of	  peptide	  to	  primary	  antibody	  aliquots	  followed	  and	  incubating	  them	  at	  
RT	  with	  occasional	  mixing.	  The	  membrane	  was	  then	  probed	  as	  described	  in	  the	  western	  blotting	  
procedure,	  using	  NFDM	  as	  block.	  PCA	  was	  then	  performed	  on	  100	  μg	  SY5Y	  WCL	  using	  20,000	  as	  the	  
molar	  excess	  factor,	  but	  was	  not	  sufficient	  to	  block	  signal	  from	  WCL.	  This	  PCA	  experiment	  was	  repeated	  
using	  100,000	  as	  the	  molar	  excess	  factor	  with	  successful	  blocking.	  	  	  
RNA	  isolation	  and	  purification	  
48	  hours	  post	  transfection,	  cells	  were	  lysed	  directly	  in	  their	  60	  mM	  culture	  dishes	  in	  1mL	  TRIzol	  
(Invitrogen,	  Grand	  Island,	  NY).	  Homogenization	  was	  done	  via	  bath	  sonication	  for	  7	  min.	  total,	  high	  
setting,	  30s	  on/off	  (Bioruptor:	  Diagenode,	  Denville,	  NJ).	  	  Samples	  were	  frozen	  at	  -­‐80°C.	  When	  thawed,	  
the	  homogenized	  sample	  was	  incubated	  at	  RT	  for	  5	  minutes.	  Insoluble	  material	  was	  then	  pelleted	  at	  
12,000	  x	  g	  for	  10	  minutes	  at	  4°C.	  250	  ug	  /	  mL	  glycogen	  was	  then	  added	  to	  the	  supernatant	  and	  mixed	  
prior	  to	  phase	  separation.	  Chloroform	  was	  then	  added	  at	  a	  ratio	  of	  0.2	  mL	  chloroform	  per	  1	  mL	  of	  Trizol,	  
vigorously	  shaken	  for	  15	  seconds,	  and	  incubated	  at	  RT	  for	  3	  minutes.	  Samples	  were	  centrifuged	  at	  
12,000	  x	  g	  for	  15	  minutes	  at	  4°C.	  The	  aqueous	  phase	  was	  moved	  to	  a	  fresh	  tube	  and	  chloroform	  
extracted	  once	  more.	  RNA	  was	  then	  precipitated	  with	  isopropanol	  at	  a	  ratio	  of	  0.5	  mL	  per	  1	  mL	  TRIzol	  
initially	  used.	  This	  mixture	  was	  gently	  mixed	  and	  incubated	  at	  -­‐20°C	  for	  15	  minutes.	  RNA	  was	  pelleted	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from	  the	  samples	  by	  centrifugation	  at	  12,000	  x	  g	  for	  10	  minutes	  at	  4°C.	  The	  supernatant	  was	  then	  
removed	  and	  RNA	  pellet	  washed	  with	  75%	  ethanol	  at	  a	  ratio	  of	  1mL	  ethanol	  per	  1mL	  TRIzol	  initially	  
used.	  The	  sample	  was	  mixed	  with	  mild	  vortexing	  and	  centrifuged	  at	  7500	  x	  g	  for	  5	  min	  at	  4°C.	  Once	  the	  
supernatant	  was	  removed,	  the	  isolated	  RNA	  was	  air	  dried	  for	  5	  minutes	  and	  redissolved	  in	  sterile	  HPLC	  
water	  at	  a	  ratio	  of	  50	  uL	  per	  5	  million	  cells	  initially	  used.	  500	  ng	  of	  RNA	  was	  run	  on	  a	  1%	  agarose	  gel	  
stained	  with	  EtBr	  at	  100	  V	  for	  45	  minutes	  and	  imaged	  with	  UV	  light	  to	  determine	  RNA	  quality.	  	  	  
	   RNA	  was	  then	  purified	  via	  2-­‐3	  DNase	  treatments	  followed	  by	  phenol	  /	  chloroform	  /	  IAA	  
extraction	  and	  ethanol	  precipitation.	  DNase	  treatments	  were	  performed	  by	  incubating	  isolated	  RNA	  
with	  RNase-­‐free	  DNase	  at	  a	  ratio	  of	  1	  unit	  per	  ug	  of	  RNA	  with	  10x	  DNase	  reaction	  buffer	  (NEB,	  Ipswich,	  
MA)	  at	  37°C	  for	  30	  minutes.	  Phenol/chloroform/IAA	  (25:24:1)	  was	  mixed	  at	  an	  equal	  volume	  (at	  least	  
100	  uL,	  brought	  up	  to	  volume	  with	  sterile	  HPLC	  water)	  to	  DNase	  treated	  RNA	  and	  spun	  down	  at	  16,000	  
rpm	  for	  5	  minutes	  at	  4°C.	  The	  aqueous	  layer	  was	  mixed	  with	  an	  equal	  volume	  of	  chloroform	  and	  spun	  
down	  at	  16,000	  rpm	  for	  5	  minutes	  at	  4°C.	  This	  chloroform	  extraction	  was	  repeated.	  The	  sample	  was	  
then	  ethanol	  precipitated	  using	  3x	  the	  reaction	  volume	  of	  100%	  EtOH,	  incubated	  at	  -­‐20°C	  for	  20	  
minutes,	  and	  then	  centrifuged	  for	  20	  minutes	  at	  16,000	  rpm..	  Supernatant	  was	  removed	  and	  the	  RNA	  
pellet	  was	  washed	  with	  1	  volume	  of	  75%	  EtOH,	  followed	  by	  centrifugation	  at	  16,000	  rpm	  for	  5	  minutes	  
at	  4°C.	  Supernatant	  was	  removed	  and	  the	  RNA	  containing	  pellet	  was	  air-­‐dried	  for	  5	  minutes.	  RNA	  was	  
resuspended	  in	  30	  μL	  HPLC	  water,	  checked	  for	  quality	  on	  an	  agarose	  gel	  as	  described,	  reverse	  
transcribed,	  and	  amplified	  using	  human	  12S	  rRNA	  primers	  to	  check	  for	  DNA	  contamination.	  This	  was	  
repeated	  until	  no	  DNA	  contamination	  was	  seen	  in	  the	  no	  RT	  control	  on	  a	  2%	  agarose	  EtBr	  gel	  after	  30	  
cycles	  of	  PCR.	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Site-­‐directed	  Mutagenesis	  
Site-­‐directed	  mutagenesis	  was	  carried	  out	  on	  the	  pDest	  constructs	  to	  delete	  all	  sequence	  between	  the	  3'	  
end	  of	  the	  CMV	  promoter	  to	  the	  coding	  sequence	  of	  the	  respective	  PGC-­‐1α	  isoform.	  See	  table	  2-­‐1	  for	  
primer	  sequences	  and	  conditions.	  Site-­‐directed	  mutagenesis	  was	  carried	  out	  using	  the	  Quikchange	  II	  kit	  
(Agilent,	  Santa	  Clara,	  CA),	  following	  manufacturer's	  instructions.	  Colonies	  were	  PCR	  colony	  screened	  
using	  a	  standard	  forward	  CMV	  primer	  (operon)	  and	  a	  reverse	  primer	  in	  exon	  3	  or	  3a.	  Pure	  clones	  which	  
contained	  the	  correct	  sized	  amplicons	  (382	  bp	  for	  PGC-­‐1α-­‐b-­‐3T1	  ATG2	  in	  pDEST40;	  136	  bp	  for	  PGC-­‐1α-­‐a	  
in	  pDEST26	  CT	  FLAG)	  visualized	  on	  an	  EtBr	  gel	  were	  CMVf	  standard	  primer	  (Operon)	  and	  a	  reverse	  
primer	  set	  in	  either	  the	  V5	  (for	  pDest40).	  A	  correct	  and	  high	  quality	  sequence	  clone	  was	  chosen	  and	  was	  
midi-­‐prepped	  for	  subsequent	  transfection.	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CHAPTER 3 
RESULTS 
 
 
 
 
PGC-1α isoform b transcripts are expressed at much lower levels than that of isoform A 
transcripts in human brain 
Our lab identified an upstream alternative exon 1b in human skeletal muscle mRNA via 5’ RACE 
(Rapid Amplification of cDNA ends), and then verified the existence of this transcript in human 
brain for the first time (Lochmann, T. unpublished data). Considering previous findings of PGC-
1α isoform a (canonical transcript) downregulation in Parkinson’s disease human prefrontal 
cortex (PFC), we wanted to investigate the expression of this isoform in comparison to 
canonical in healthy vs. Parkinson’s disease states (Thomas, Keeney, and Bennett, 2012). The 
expression levels of PGC-1α isoforms a and b were quantified via qRT-PCR from 6 human 
prefrontal cortex samples, 3 from Parkinson’s disease patients and 3 from age-matched healthy 
patient samples. Locations of the primer sets that were used to distinguish isoform a versus 
isoform b transcripts, versus total PGC-1α is shown in Fig. 3-2A. Figure 3-2B shows that there is 
variability in relative RNA abundance between patient samples for each transcript, however 
there does not appear to be a disease specific difference in transcript levels for either PCG-1α-a 
or PGC-1α-b in these samples. More importantly, Fig. 3-2B shows that PGC-1α isoform b 
transcript levels are present at 15 to 20 fold lower than those of isoform b transcript, with 
isoform a levels on the same order of magnitude as total PGC-1α. Overall, this data shows that 
PGC-1α isoform b transcripts are expressed at much lower levels than that of canonical form of 
PGC-1α (isoform A), regardless of disease state in the case of Parkinson’s disease. 
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Fig. 3-2: DNA methylation correlates with isoform specific PGC1a expression levels in human brain. A 
total of 13 CpG sites located within 1000 bp of the TSS were analyzed. (A) Transcript map showing locations of 
isoform A specific (299 bp), isoform b specific (168 bp), and total PGC-1α (148 bp) primer sets used in qRT-PCR. 
Gray region indicates coding sequence. (B) Relative RNA abundance of total PGC-1α (upper panel), isoform b 
(middle), and isoform A (canonical PGC-1a, lower) normalized to control data (average of GAPDH and CYC9 
mitochondrial reference genes, chosen for least degree of variance). n=3; mean of each normalized to control, 
depicted. (C) 454 high-throughput bisulfite sequencing of PGC1a isoform A and B promoter regions expressed 
as percent methylated cytosines over all reads (range n = 1200 to 200k reads per strand) at each CpG 
dinucleotide located within 1000bp of the transcription start site (TSS). Isoform b (upper) Isoform A (lower). 
Sample #s122, 170, 174 denote healthy patient PFC brain samples; 191, 203, 213 denote age-matched 
Parkinson’s patient prefrontal cortex samples. 
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 PGC-1α isoform b promoter region is highly methylated 
To investigate whether this difference in isoform b transcript expression is regulated via 
epigenetic mechanisms, we applied first a bisulfite clone and sequence method with an n of 3-4 
clones per amplified promoter region. The region amplified spanned 1.5 kb upstream of the TSS 
of the same samples utilized in the transcript expression studies. This preliminary study yielded 
interesting results, showing little to no methylation of all potential CpG dinucleotides 1.5 kb to 
0.75 kb upstream of the TSS (<20% per CpG dinucleotide, Fig. 3-1) contrasted by a high 
degree of methylation closer to the transcription start site (TSS) (>75% per CpG dinucleotide, 
Fig. 3-1). To increase the statistical power of our data to obtain more definitive results, we 
utilized the method of 454 high-throughput pyrosequencing of bisulfite-treated DNA. Promoter 
regions were amplified on 7 separate amplicons for isoform a and 3 for isoform b spanning 1 kb 
prior to the TSS, and analyzed as pools using patient sample specific bar codes.  Read depth 
for the different amplicons varied between ~1200 reads to ~200,000 reads per strand. This high-
throughput method largely agreed with our low-power clone and sequence results (Fig. 3-1, 2C). 
After CpG #9 (positioned 350 bp upstream of the TSS), all but 1 CpG methylation site is 
methylated at levels >50% across all reads. At this single CpG dinucleotide, located ~250bp 
upstream of the TSS, there is a distinct drop in methylation evident across all reads and for all 
samples. In contrast, isoform a methylation levels remained below 20% across all possible CpG 
sites. Overall, Fig. 3-2C shows that the isoform b promoter region is methylated to a much 
higher degree than that of canonical PGC-1α (isoform A). Isoform b is highly methylated (>60%) 
across most potential methylation sites (CpG dinucleotides), with increases as the TSS is 
approached.  Although no disease-specific correlations between transcript levels or DNA 
methylation were observed, we conclude that isoform b expression is controlled in part through 
epigenetic means, correlating with DNA methylation associated silencing, and that the low 
levels of transcript expression observed potentially are due to the distinct drop in methylation at 
350 bp prior to the TSS.  
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PGC-1α isoform b transcript alternative splice variant found in human skeletal muscle 
and brain 
From the 5’ RACE on human skeletal muscle (HSM) conducted in our lab which identified 
human PGC-1α-b, one clone was identified which contained alternative splicing between exons 
3 and 4 (Fig. 3-3A). Sequencing revealed that 82 bp of the intronic region between exons 3 and 
4 were retained in the mature transcript, resulting in the formation of an early stop codon 21 bp 
into the 82 bp insertion. This variant transcript was named PGC-1α-b-3T1.  We investigated 
whether this isoform variant also existed in other tissues, since it had not been reported 
previously in the literature. We conducted RT-PCR on our human brain RNA samples to 
determine the presence of this alternatively spliced isoform b variant. Using a sense primer in 
exon 1b and an antisense primer that spanned the insertion-3’ UTR boundary (only extending 
into the insertion by 3 bases, we were able to ensure that the primer set should not amplify off 
immature transcript (Fig. 3-3A). A no RT control was used to validate that there was no genomic 
DNA present in the cDNA. This primer set was expected to produce a 571 bp amplicon. End-
point RT-PCR revealed a band of the expected size, 571 bp, on an ethidium bromide UV-
visualized agarose gel (Fig.3-3B). This confirmed the presence of PGC-1α-b-3T1 transcript not 
only in human skeletal muscle, but also in human brain. Due to the early stop codon introduced 
in this novel PGC-1α-b transcript variant, a severely truncated protein would be produced (Fig. 
3-3C). If PGC-1α-b-3T1 is translated endogenously in humans, we should be able to detect a 
147 amino acid protein (15.8 kDa) in brain or muscle cell lysates using the isoform b specific 
primary antibody that had been developed for us (Genscript).   
Bacterial expression and purification of recombinant GST/PGC-1a-b-3T1 fusion protein   
In order to optimize our PGC-1α isoform b specific primary antibody, we needed to produce 
pure, recombinant protein containing the epitope the antibody was raised against.	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Figure 3-3: Identification of a new PGC1a isoform, PGC-1α-b 3T1 (exon 3 Truncated). (A) Schematic of 
PGC-1α-a (canonical isoform A) and PGC-1α-b (isoform b, isoform b 3T1) transcripts. Boxes indicate exons, lines 
indicate spliced introns, arrows indicate primer set location, red asterisks indicate stop codons in resultant CDS. 
(top) Isoform a (middle) Isoform b; transcript differs from isoform a only in the first exon. Isoform b has been 
found to extend to exon 13 in mice, with an unknown 3’ end in human (Miura et al., 2008). (bottom) Isoform b 
variant 3T1 (PGC-1α-b-3T1), includes an 82 bp extension on exon 3 derived from intron 3, with an early stop 
codon located 21 bp after exon 3. (B) End-point RT-PCR of PGC-1α-b-3T1 transcript in HSM and human brain. 
571 bp bands represent the identification of mature transcript in both HSM (left) and human brain (right No RT 
control indicates lack of genomic DNA contamination. (C) Schematic of predicted retained domains of PGC-1α-b-
3T1 vs. PGC-1α-b. (HCF: host cell factor domain; NLS: nuclear localization signal; P = phosphorylation site; RS = 
arginine / serine rich domain; RRM = RNA binding motif  - both RNA processing domains)     
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Considering that a transcript coding for a short version of PGC-1α isoform b had just been 
validated in a previous experiment (PGC-1α-b-3T1; see Fig. 3-3), we wanted to produce the 
predicted protein as a recombinant protein in bacteria. We originally chose this protein because 
it (1) contained our epitope, allowing us to optimize our antibody and determine its specificity 
and limit of detection; (2) had a low hydrophobicity index, indicating that it should be soluble and 
thus easily purified and potentially active to be able to probe its functions in vitro at a later time; 
and (3) it could be added to our whole cell lysates to determine the specificity of our antibody 
against a mammalian cell background; (4) it was a novel transcript, therefore we needed to 
know if it could produce viable protein and potential functions of that protein.  
This protein was ultimately difficult to express in bacteria, however, and was therefore 
cloned as an N-terminal GST fusion protein instead of untagged, native PGC-1α-b-3T1.  We 
used the pET41a vector, since it contained NT GST, which would aid in solubility, translation 
efficiency, and ease of purification of the target PGC-1α-b-3T1protein (Fig. 3-4A). pET41a also 
contained NT and CT 6xHis tags which provided us with the additional route of Ni-NTA affinity 
purification if the glutathione resin alone did not yield a pure enough fraction (Fig. 3-4A). We 
found that glutathione resin-based purification alone yielded protein of greater purity than Ni-
NTA followed by glutathione resin purification (Fig. S2). BL21 DE3 competent cells with a 4 hour 
1mM IPTG induction at 37˚C in LB were the conditions used to express the recombinant protein 
in bacteria, based on several small scale optimization experiments (Fig. S1).  
The recombinant protein had a predicted size of 50 kDa. The protein we obtained from 
purification, however, migrated at ~60 kDa on SDS-PAGE gel, with several less abundant lower 
molecular weight bands occurring at ~40 kDa, ~30kDa, and ~26 kDa (Fig. 3-4B).  
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Fig. 3-4: Bacterial expression and purification of recombinant GST / PGC-1α-b-3T1 (A) vector map of 
pET41a after subcloning of PGC-1a. This vector produced an N-terminal fusion protein of approximately 50 kDa. 
(B) Coomassie-stained SDS-PAGE of recombinant PGC-1α-b-3T1 production and purification, using glutathione 
agarose resin. Target protein ran at ~60 kDa. Fractions of purifications steps were loaded with material from 
equal numbers of cells based on OD600. (C) Immunoblot of GST-PGC-1a-b-3T1 recombinant protein using GST 
monoclonal antibody. 60 µg total protein was loaded for WCL and 10 µg total protein was loaded for the flow 
through and elution lanes. Chemiluminescent detection with full-strength dura ECL substrate, 4s exposure. (D) 
Immunoblot of purified recombinant GST-PGC-1a-b-3T1 fusion protein with PGC-1α isoform b specific primary 
antibody.  Protein loaded was as in C above. A 1:5,000 dilution of secondary antibody was used. Exposed with 
full-strength dura ECL substrate for 4s. 
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In order to determine if the 60 kDa band was indeed full-length recombinant protein, the 
purification fractions were probed with both GST and our PGC-1α isoform b specific primary 
antibodies. From these western blots, it was evident that all four bands visible on the 
Coomassie stained gel contained GST (Fig. 3-4C), while only 3 contained PGC-1α-b-3T1 (Fig. 
3-4D). The three bands detected by the isoform b antibody included all but the lowest (~26 kDa) 
band detected via Coomassie staining (Fig. 3-4D). These results showed that the protein was 
being degraded in some way prior to purification, since these bands are visible in lysate at 4 
hours post-induction (Fig. 3-4C-D).  
Since the specificity of our PGC-1α isoform b antibody had yet to be validated, another 
method was necessary to confirm that each band was truly a degradation product and not a 
contaminating bacterial protein. Mass-spectrometry of the bands in the Coomassie-stained gel 
was employed to confirm that our epitope was present, and also to confirm that the final purified 
product contained only our recombinant PGC-1α-b-3T1 protein. This verification was necessary 
for the intended use of PGC-1α-b-3T1 to optimize our PGC-1α isoform b specific primary 
antibody.   
Mass spectroscopy validation of recombinant protein identity and antibody specificity 
via epitope peptide MS identification 
Since there were multiple protein bands visualized from our purification that were not of 
the expected size, mass spectrometry was necessary to verify the identity of the recombinant 
protein. From immunoblots, it was determined that the upper band (~60 kDa) is most likely the 
full-length pure recombinant protein that was expected to run at 50 kDa on SDS-PAGE (see Fig. 
3B-D). The remaining bands were presumed to be degradation products of the expressed 
construct. Mass spectrometry analysis was also necessary because although our PGC-1α 
isoform b specific primary antibody was able to detect protein in our elution fractions, the  
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  Fig. 3-5: Mass spectroscopy validation of recombinant protein identity and antibody specificity using 
peptide MS identification. (A) SDS-PAGE gel of purified recombinant GST/PGC-1a-b-3T1 fusion protein used 
for mass spec analysis (left). Bands 1-4 are ordered according to size (~60, 40, 30, and 26 kDa). Bands were 
excised, subjected to cleavage by trypsin, followed by MS/MS analysis. Tryptic peptides mapped to recombinant 
protein sequence as confirmed by SEQUEST (right). (B) Identified tryptic peptides across all samples. Bands 
refer to (A). The green region denotes the epitope location. Percent coverage is percent of amino acids identified 
from GST/ PGC-1α-b-3T1 fusion construct. (C) Representative spectrum of MS/MS acquisition for peptide 
containing the epitope for our PGC-1α isoform b specific primary antibody. B ions are peptides which increase in 
size from the NT. Y ions are peptides which increase in size from the CT.  Xcoor cut- offs were 1.5 for a plus 1 
charge state, 2.0 for a plus 2 charge state, and 2.5 for a plus 3 charge state. 
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antibody had not yet been validated nor evaluated for specificity. The recombinant protein would 
actually be the tool required to optimize our primary antibody. Mass spectrometry data would 
enable us to determine which bands contain the epitope of our antibody. If those epitope-
containing bands were the same which were identified by our antibody in immunoblots, mass 
spectrometry analysis would thus provide support for validation of our antibody.  
In the GST portion of the fusion construct, there were several excellent candidate tryptic 
peptides, however, we expected that trypsin cleavage would not yield many peptides in the 
PGC-1α-b-3T1 portion of our fusion protein that could be efficiently fingerprinted for this method. 
Most potential tryptic peptides formed from PGC-1α-b-3T1 were not of the optimal size or 
charge state for detection. One predicted optimal tryptic peptide within the PGC-1α-b-3T1 
portion of our fusion protein contained the epitope to our PGC-1α isoform b specific antibody: 
MLGLSSDSILKC.  Considering verification of this peptide in our sample was the objective of our 
analysis, and no other proteases or combination thereof would give us coverage of this epitope 
as well as good coverage of GST, we decided to use trypsin to accomplish cleavage of the 
proteins in our gel for MS/MS analysis. Each band visible on the Coomassie stained SDS-PAGE 
gel was excised, and the protein contained within it was then cleaved by trypsin (Fig. 3-5A). The 
resultant peptides were extracted and analyzed via MS/MS. 	  
Upon mass spectrometry spectra analysis by SEQUEST, the upper band (band 1, ~60 
kDa) was verified as our fusion construct with 39.23% coverage (Fig. 3-5A). Percent coverage is 
defined here as the percent of total amino acids identified from GST/ PGC-1α-b-3T1 fusion 
construct. The peptides identified from the remaining three lower molecular weight bands 
aligned with the recombinant protein sequence with 29.48, 29.23, and 26.76 percent coverage, 
respectively (fig. 4A- B). Bands 1-3 (~60, ~40, and ~ 30 kDa) all contained the tryptic peptide 
representing the epitope to our PGC-1α isoform b specific primary antibody (Fig. 3-5A-C). This 
peptide is positioned at amino acids 284-299 of the 441 aa fusion construct, with sequence 
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GSTHMLGLSSMDSILK. The epitope is located at position 288-300 (MLGLSSMDSILKC), 
therefore only the last amino acid was not represented in the peptide containing the epitope. In 
band 4 (~26 kDa), no peptides associated with the PGC-1α-b-3T1 portion of the fusion construct 
were identified. Therefore the percent coverage score only represents the GST portion of the 
fusion construct. 
The results therefore showed that 3 out of the 4 bands visible on the Coomassie stained 
SDS-PAGE gel contained the epitope of interest, with the 4th band containing only GST. This 
result, along with >20% coverage of each of the bands for the fusion construct, gave concrete 
evidence that the GST PGC-1α-b-3T1 fusion construct was in fact the identity of our 
recombinant protein. This recombinant protein would now be the tool to validate and optimize 
our PGC-1α isoform b specific antibody. Considering the first immunoblot using this antibody 
selectively identified the 3 out of 4 bands which contained the epitope, the ability of the antibody 
to detect its target protein with some degree of specificity was apparent. This specificity of 
detection was observed on a minimal protein background, however, and alone could not 
completely reveal the degree of specificity of this antibody. This validated recombinant protein 
would serve as a means to optimize the western blotting conditions for this antibody to 
ultimately establish its limit of detection and specificity.	  
	  
PGC-1α isoform b specific antibody: optimization, limit of detection, and specificity 
In order to probe for endogenous human isoform b proteins and variants, it was necessary to 
develop an antibody specific to all possible forms of PGC-1α isoform b. The only location for 
such an antibody to be directed against was within the coding sequence resulting from exon 1b. 
This epitope was the only known distinction between isoform a and isoform b that would 
positively identify isoform b (Fig. 3-6A). Now that several isoform b variant transcripts have been 
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discovered, antibody directed against this epitope location should be able to detect any protein 
translated using exon 1b.  
The optimization of this antibody will allow probing for all of the possible PGC-1α-b 
variants. Based on predicted size of these variants from mature transcript sequences (see Fig. 
3-6 and table 1-2), these variants can be identified in cell lines and tissues. Based on our 
studies and current literature (see table 1-2) we predict 4 isoform b variants of molecular mass 
90, 50, 40, and 17 kDa produced from various isoform b specific transcripts (Fig. 1-5, table 1-2).  
However, there is currently no information about endogenous protein production from any of 
these transcripts. If proteins of a predicted size were specifically detected by the isoform b 
antibody, the protein could be considered to be an endogenous functioning entity in that tissue 
type. With this antibody tool optimized and validated, we can then begin to further characterize 
endogenous protein-producing PGC-1α-b variant isoforms both in vivo and in vitro to better 
understand their function. More importantly, with this optimized antibody, we can eventually 
determine how PGC-1α isoform b and its variants are different from each other and PGC-1α-a 
in terms of function, regulation, and localization. Knowledge of the characteristics which are 
unique to each isoform could allow PGC-1α functions to be pharmacologically targetable in a 
spatio-temporal manner. Thus diseases which have a pathology attributed to misregulation of 
PGC-1α can have novel, specific treatment options.  
The antigenicity within exon 1b was low based on Genscript analysis, however the 
antibody raised to this region (Fig. 3-6A) had a high titer in initial ELISA experiments 
(1:512,000). We therefore expected our antibody to effectively be able to detect PGC-1α-b and 
any of its possible variants. We also expected it to be specific, as a BLAST search did not 
reveal any similar human sequences. It is difficult to predict nonspecific binding, however. We 
aimed to determine the optimal western blotting conditions in order to obtain the highest degree 
of signal and lowest background, while retaining specificity.  
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Fig. 3-6: PGC-1α-b specific antibody: optimization, limit of detection, and specificity (A) Epitope location of 
PGC-1a-b isoform specific antibody: Amino acid sequence of PGC-1α-a vs. PGC-1α-b. Epitope location (blue) is 
unique to PGC-1a-b. (B) Antibody sensitivity using recombinant GST / PGC-1a-b-3T1 fusion protein. Optimized 
1:100 dilution of primary PGC-1a-b isoform specific Ab, 1:30,000 dilution of secondary Ab with T20 Starting Block 
(Thermo). Exposed in full dura ECL substrate for 2 minutes. (C) Peptide competition assay (PCA)  optimization. 
0-20,000: range of molar excess of peptide to PGC-1α-b antibody used. Exposed in full dura for 4s. Peptide used 
shown in blue in part A. (D) Degree of specificity of PGC-1α-b specific primary Ab by PCA. 0-100,000: molar 
excess of peptide to PGC-1α-b antibody used. Each lane contained 100 ug of SY5Y WCL per lane. Arrows 
indicate bands in which decreased signal is observed upon peptide competition, indicating specific binding.  Blot 
was exposed with 1/8 dura for 4s. 5% non-fat dry milk in TBS-T was used as the blocking buffer in parts B-D.	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     We assumed that levels of protein would be minimal for PGC-1α-b and its variants under 
normal conditions. This prediction was based upon qPCR data showing that all possible isoform 
b variant transcripts combined are present at 1/10th the levels of PGC-1α-a containing 
transcripts in human brain (see figure 1B) and several other tissues, including kidney (Ruas et 
al., 2012). We make the assumption that transcript levels would reflect levels of protein; 
however, this is not always true. Based on tissue specific expression levels, we chose SH-
SY5Ys (human neuroblastoma) and HEK293 (human embryonic kidney) for initial antibody 
tests. Endogenous PGC-1α-a was difficult to detect even with commercially available 
antibodies, based on previous experience in our lab. We assumed that isoform b would be 
present in the nanogram range at best, and titrated from 1 µg down to 1 pg of 60 kDa 
recombinant protein. Probing with a previously tested 1:16,000 dilution via western blot revealed 
that this optimized dilution could only detect down to between 1 µg and 100 ng of PGC-1α-b 
protein (Fig. S4). Therefore, several primary antibody concentrations were assessed, and a 
1:100 dilution of the primary antibody yielded detection down to 1 ng (Fig. 3-6B). Although we 
could detect 1 ng, conditions needed to be further optimized to reduce background. By 
switching to blocking with 5% milk in TBS-T versus starting block (Thermo), a dramatic change 
in background levels were observed, eliminating all background even with a 2 minute exposure 
using full strength dura ECL substrate (Fig. S5). Combining information gained from these 
optimization experiments, the final optimized conditions were 5% milk in TBS-T blocking buffer, 
a 1:100 dilution of PGC-1α isoform b specific primary antibody, and a 1:35,000 dilution of goat 
anti-rabbit (GαR) HRP-conjµgated secondary antibody, probed in full to ½ dura with a 2min 
exposure (recombinant and WCL, respectively).  
With the optimized conditions and limit of detection determined, the specificity of our 
PGC-1α- b specific primary antibody was assessed. Although our antibody already showed no 
non-specific signal on a bacterial lysate background (Fig. 3-4D), specificity on a mammalian 
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whole cell lysate background had not yet been determined. The gold standard to determine 
antibody specificity is the Peptide Competition Assay (PCA), in which primary antibody is 
incubated with its matching immunizing peptide prior to immunoblotting; this way, only 
nonspecific binding should be detected. The recombinant PGC-1α-b-3T1 protein was used to 
optimize peptide competition conditions. We determined the molar excess factor of peptide to 
antibody needed to block detection of recombinant protein, as well as peptide-antibody 
incubation conditions. After several tries, the molar excess factor which resulted in 100% 
blocking of 10 ng of recombinant protein was 20,000 (Fig. 3-6C). The optimal incubation 
conditions were determined to be 2 hours at room temperature with occasional mixing (Agrisera 
PCA protocol incubation conditions). Most importantly, peptide needed to be dissolved in pH 5.5 
buffer in order to prevent disulfide bond formation prior to being incubated with primary 
antibody. Since this peptide was KLH-conjµgated, there is a Cys at the NT of the peptide in 
addition to the internal Cys at the CT of the peptide; if a disulfide bond formed, peptide would be 
bound to itself and would not be able to bind primary antibody, minimizing any blocking effect.   
Once peptide blocking conditions were determined, the peptide competition experiments 
were conducted on WCLs. SH-SY5Y cells were chosen because they are a human neuronal 
cell line and several new PGC-1α isoforms had been reported in brain, including a mitochondrial 
isoform with unknown parent transcript. We had also found isoform b transcripts in human brain 
tissue (Fig. 3-2A-B, Fig. 3-3B). Blocking with 20,000 molar excess of peptide was not enough to 
fully block any signal using 100 µg SY5Y WCL (Fig. S6). The molar excess factor was then 
increased to 100,000, which was enough to cause a visual reduction in signal after exposure in 
1/8 dura ECL substrate for 4s from 5 bands: ~90, 50, 35, 25, and 17 kDa. Of these 5 bands, the 
17 kDa band was completely competed by the peptide. Signal for the ~90 kDa band was 
reduced by 64%. For the ~50 kDa band, signal was reduced by 62%. For the ~35 kDa band, the 
degree of signal reduction could not be determined because the band was overexposed. Even 
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at 1/16 dura ECL substrate, this band was overexposed. This experiment needs to be repeated 
to determine the exact percent reduction in signal for this 50 kDa band. For the 25 kDa band, 
signal was reduced by 64%. All percent reductions in signal from competing peptide were 
determined by ImageJ analysis (Rasband, W.S.; NIH).   
Expected protein sizes were between 90 and 114 kDa for PGC-1α-b, and ~ 15 kDa 
representing PGC-1α-b-3T1. Other potential expected sizes include the remaining isoform b 
variants: PGC-1α-2 (41kDa) and PGC-1α-4 (29 kDa) (Ruas et al, 2012). There could also 
potentially be isoform b versions of NT-PGC-1α (38 kDa, Zhang et al., 2009) or PGC-1α ex1-8a 
(33 kDa, Soyal et al., 2012). The parent transcript of the mitochondrial isoform of PGC-1α is 
unknown, although this isoform was identified as a 35 kDa protein in SY5Ys by immunoblot. 
This mitochondrial isoform could potentially be an isoform b variant as well. Based on these 
predicted sizes, it is likely that the 90 kDa isoform b specific protein detected is full-length PGC-
1α-b (resultant CDS ending in exon 13). PGC-1α-2 was shown to migrate closer to 50 kDa, and 
could therefore be represented in the 50 kDa isoform b specific protein which was detected. The 
35 kDa protein detected is a likely candidate for mitochondrial PGC-1α, both observed to 
migrate at 35 kDa in SH-SY5Y cells. It is also a possibility that this 35 kDa protein detected 
represents an isoform b version of PGC-1αex1-8a, migrating a few kDa higher than predicted. It 
is possible that the identity of the mitochondrial isoform is the isoform b version of PGC-1α ex1-
8a. No predicted size protein matches well with the 25 kDa protein detected. There is a 
possibility that this represents PGC-1α-b-3T1, but it would be migrating 10 kDa higher than 
expected. The other possibility is that this 25 kDa species represents a novel isoform b variant.  
The 17 kDa band detected to be specific for the isoform b specific primary antibody most likely 
represents PGC-1α-b-3T1, migrating slightly higher than expected.  
Overall these results show that our PGC-1α-b specific antibody can detect PGC-1α-b 
protein and that this detection is specific, however, there are several nonspecific binding events 
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observed on immunoblots. There is potential confirmation of human versions of several 
predicted mouse isoform b variants. There is also potential confirmation of isoform b versions of 
several isoform a variants. Most intriguingly, the identity of the 35 kDa mitochondrial PGC-1α 
isoform may be solved. It migrates at the same size as an isoform b specific detected protein. 
An isoform a variant could also migrate at this size, and thus the true identity of the 
mitochondrial isoform could potentially be PGC-1α-b-ex8a. This is the first step in further 
characterizing these isoforms and understanding their function.  
PGC-1α isoform b 3T1 overexpression in HEK293 cells 
I generated CMV driven overexpression constructs containing PGC-1α-b-3T1 for 
determination of its functions in vitro. PGC-1α-a was also cloned in the same manner as PGC-
1α-b-3T1 for side-by-side comparison to canonical PGC-1α. The final constructs contained a CT 
V5 or FLAG tag for immunodetection of PGC-1α-b-3T1 and PGC-1α-a, respectively (Fig. 3-7A).  
Inclusion of epitope tags in these constructs was necessary because the antibodies we had 
used to detect PGC-1α-a (including NT ones that could also theoretically detect PGC-1α-b and 
its variants) had several nonspecific bands and did not detect endogenous PGC-1α-a even in 
recommended positive controls (Fig. S3).  The PGC-1α-b-3T1 construct was made because it 
was the only known human isoform b variant to date in which the entire CDS could be 
accounted for by the transcript. Mouse isoform b transcripts had not yet been fully identified in 
human tissues, including PGC-1α-b. Only transcript through exon 5 had been validated for 
human PGC-1α-b (Lochmann, T. unpublished data). Thus, the entire coding sequences for the 
possible isoform b transcripts in humans have yet to be determined.  Although it was not known 
whether this protein was endogenously translated in humans, it was the only validated human 
version of isoform b for which its entire coding sequence was accounted for in the parent 
transcript (see Fig. 3-3).    
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Fig. 3-7: PGC-1a-a and PGC-1a-b-3T1 overexpression in HEK293 cells (A) Lack of translation of PGC-1α 
pDEST constructs in immunoblots of HEK293 WCL. PGC-1a-a and PGC-1a-b-3T1 were cloned into pDest26-CT-
FLAG and pDEST40, respectively (see Methods, figure 1), and transfected into HEK293 cells. Positive control for 
V5 (lane 2: hDNMT1 in pDEST40) and FLAG (lane 5: wt IDH2 in pDEST26-CT-FLAG) transfected at the same 
time served as controls for epitopes, transfection, as well as vectors. Expected sizes: 180 kDa, V5+; 60 kDa, 
FLAG+; 101 kDa, PGC-1a-a; 19 kDa, PGC-1a-b-3T1. Mock transfected HEK293 WCL was used as the negative 
control and VDAC as loading control. Blots were exposed for 10 min following detection with full dura ECL 
substrate and chemiluminescence visualized via LI-COR. (B) End-point RT-PCR of RNA extracted from HEK293 
transfected with PGC-1α pDEST constructs. Sense primers were located near the 3’ end of PGC-1α transcripts 
with antisense in the fusion tags. (H: water negative control; -RT: no reverse transcriptase negative control; RT: 
reverse transcribed sample. – ctl: empty vector negative control; M: 1 kb + marker). (C) Site-directed mutagenesis 
deletion of sequence between CMV promoter and PGC-1α CDS: schematic of deleted region.	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We therefore sought to overexpress PGC-1α-b-3T1. This overexpression would initially allow us 
to determine the phenotypic effects of overexpression of PGC-1α-b-3T1 on cells. In comparison 
to endogenous levels (nontransfected) as well as overexpressed PGC-1α-a, this could provide 
initial information on conserved functional roles as well as any unique effects. Once 
overexpressed successfully, this manipulation of the amount of PGC-1α would allow us to see 
extreme effects on cells, which could eventually be contrasted by siRNA-mediated knockdown 
studies to further elucidate functional differences. We would also be able to look at changes in 
rates of mitochondrial respiration, binding interactions, and changes in levels of target genes. 
This would enable us to tease apart the specific functions of PGC-1α-b-3T1 which could 
contribute to those already attributed to PGC-1α-a.       
 We chose to transfect HEK cells with these PGC-1α constructs for their characteristic 
high transient transfection efficiencies. Also, in our lab PGC-1α-a had been previously 
transiently overexpressed in cell culture and were still viable (Shock, et al., 2011). Due to these 
results, we expected that these constructs would be easy to express in HEK293 cells. Upon 
transfection, no expression of these constructs was ever seen in western blot (Fig. 3-7B). Since 
CT fusion tags were being used to indirectly assess expression of PGC-1α, we sequenced the 
plasmids used in our transfections to determine that the sequence had not rearranged during 
large scale endotoxin-free preparation.  DNA sequencing validated that PGC-1α was in frame 
with the tags used for immunodetection, and had not rearranged. In our lab, murine mtDNMT1 
had been cloned into gateway vectors with no success in translation, although RT-PCR studies 
showed that they were being transcribed (Burton, E., unpublished observations). The problems 
expressing this protein were resolved upon removal of the Gateway attB sites and additional 
nucleotides between the end of the CMV promoter and the CDS. We therefore asked whether 
transcripts could be detected in transient transfection with the PGC1a expression vectors. Cells 
from transient transfections of these PGC-1α constructs were harvested and RNA extracted. 
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Primer sets to detect transcript expression were designed with sense primers specific to PGC-
1α-a or PGC-1α-b and antisense primers specific to its respective tag in the gateway vector 
(FLAG or V5). If transcription was taking place, an amplicon of 136 bp for PGC-1α-a and 382 bp 
for PGC-1α-b-3T1 was expected (Fig. 3-7B)  
Upon RT-PCR, bands of the expected size were visualized with no genomic DNA 
contamination shown from the lack of bands in the no reverse transcriptase control. From these 
results, it was determined that these constructs were indeed being transcribed. I used site-
directed mutagenesis to remove the sequence between the CMV promoter and the CDS. This 
was successful for the PGC-1α-b-3T1 construct only. However, considering a new PGC-1α NT 
antibody had been made commercially available with success in detecting PGC-1α-a, it was 
decided that the construct made by Lisa Shock mentioned previously would be used to transfect 
PGC-1α-a for direct comparison to PGC-1α-b-3T1 (Shock et al., 2011). This experiment will be 
conducted in the near future.   
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CHAPTER 4 
DISCUSSION 
 
 
Transcriptional regulation of PGC1a: insights from mRNA expression and genomic DNA 
methylation studies 
Our results suggest that DNA methylation may play a key role in the differential transcriptional 
regulation of PGC-1α-b versus canonical PGC-1α-a. PGC-1α-b is expressed 15 to 20 fold lower 
than PGC-1α-a, based upon normalized qRT-PCR data of human brain samples (see Fig. 3-
2B). A high degree of methylation, known to correlate with gene silencing in many genes, was 
observed at each CpG 1 kb upstream of the transcription start site within the promoter region of 
PGC-1α-b (see Fig. 3-1,2C). Little to no methylation was observed in the promoter region of 
PGC-1α-a (see Fig. 3-2C). This difference in gene silencing methylation status could explain the 
difference in transcript expression between the two isoforms. It is of importance to note that 
PGC-1α does not contain CpG islands even 20 kb upstream of the TSS, and therefore is 
considered to be a CpG sparse promoter. Tissue-specific gene-silencing is frequently found in 
CpG sparse promoter regions, however (Nagae et al., 2011; Racanelli et al., 2008; Rishi et al., 
2010).  
     The literature has recently reported several PGC-1α-a and PGC-1α-b variants, as described 
in this thesis (5 PGC-1α-a variants: Soyal et al., 2012; Spiegelman et al., 1998; Zhang et al., 
2009; 3 PGC-1α-b variants: Miura et al., 2008; Ruas et al., 2012). Although we have not yet 
verified the 3’ end of the mature transcripts in human brain (transcripts have been verified 
through to exon 5), our transcription data would apply to all currently established isoform a and 
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b variants of PGC-1α because all transcripts thus far reported contain exon 1a or exon 1b and 
exons 2 and 3, which is where our qPCR primers were located (see Fig. 3-2A). Most of these 
isoforms have been found in rodents, and we are currently conducting 3’ RACE experiments to 
verify the existence of any of these isoforms, or potential new alternative splice variants, in 
human tissues, specifically human skeletal muscle and brain. The lab is also currently 
conducting 5' RACE of human brain to determine whether any additional alternative spliced 
transcripts upstream of isoform b exist. From our previous 5’ RACE experiments, however, we 
know that exon 1a and exon 1b are two primary exons with unique promoter regions, which are 
transcribed in human skeletal muscle. For the studies reported here, cDNA was made from 
human prefrontal cortex. Other  published 5' RACE studies using RNA from whole human brain 
samples found transcripts with TSS much farther upstream of exon 1b (Soyal et al., 2012), but 
failed to identify any isoform b promoter based transcripts. One potential explanation for this is 
that the isoforms we found are region-specific to the prefrontal cortex. Since we found that these 
isoforms are very low in abundance, they would be enriched in our samples compared to whole 
brain homogenates if regional specificity was a factor.  
     The first instance of PGC-1α-b identification was from studies using mouse skeletal muscle 
RNA (Miura et al, 2008). Similar to our findings, Miura and colleagues showed that transcript 
levels of PGC-1α-b were lower than that of PGC-1α-a at basal transcription levels. After mice 
were exercised, however, they found that levels of PGC-1α-b rose 100% higher than basal or 
exercised levels of PGC-1α-a 3 hours post exercise, becoming the predominant isoform. This 
effect was time-dependent and transient, with maximal PGC1a-b levels 30 min post exercise 
(700% increase relative to PGC-1α-a levels), and returning to basal levels between 6 and 24 hr 
post exercise (Tadaishi et al., 2011). Thus, it appears that, in skeletal muscle the isoform b 
promoter is poised for rapid activation.  If a similar phenomenon were also occurring during 
periods of metabolic stress due to energy consumption in brain, then we would expect that the 
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methylation levels we have measured in this promoter might also include substantial levels of 
hydroxymethylation, which cannot be distinguished from methylation by bisulfite sequencing. 
Hydroxymethylation has been shown to occur in the nucleus as an intermediate on the path to 
demethylation, and therefore could offer this rapid switching mechanism under periods of 
metabolic stress (Tahiliani et al., 2009). Dr. Timothy Lochmann in our lab is currently conducting 
ChIP studies on the PGC-1α-a vs. b promoters. Thus far, he has shown that there are low levels 
of activating histone marks, but relatively low levels as well of repressive marks, suggesting a 
poised promoter in brain. The distinct drop in methylation levels that is seen 250 bp upstream of 
the TSS occurs at the proximal promoter, which is generally where polymerase II binds to begin 
transcription (see Fig. 3-2C). There could potentially be an area of heavy hydroxymethylation in 
the methylated promoter surrounding this region, which could lead to the rapid increase in 
transcript levels seen upon exercise. Future studies will look into locus-specific levels of 
hydroxymethylation to see if the proposed rapid switch demethylation regulation mechanism is 
occurring.  
 
A novel PGC-1α-b variant transcript allowed validation and optimization of PGC-1α-b 
specific antibody.  
The results from our 5’ RACE and RT-PCR experiments revealed that PGC-1α-b-3T1 
transcript is expressed in human skeletal muscle and brain (see Fig. 3-3B). The resultant 
protein of the PGC-1α-b-3T1 transcript would be truncated – in comparison to full length PGC-
1α-b – due to the introduction of an early stop codon via alternative splicing between exons 3 
and 4 (See Fig. 3-3A). Due to this truncation, only the first 147 amino acids of PGC-1α-b would 
be retained (see Fig. 3-3C). It was expected that this transcript may not be found in our human 
brain prefrontal cortex samples, even though its parent transcript, PGC-1α-b, is transcribed 
there (Lochmann, T.  unpublished findings).  This uncertainty stemmed from the studies in 
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whole brain (Soyal et al., 2012) in which they failed to find this variant, suggesting that the PGC-
1α variants exhibit a  tissue-specific or even tissue region-specific pattern of expression. 
We now have some evidence that PGC-1α-b-3T1 is translated endogenously (see fig. 3-
6D), although a functional assay is necessary to prove functionality. One such experiment could 
be cotransfection of this construct with a plasmid containing a reporter gene fused to the coding 
sequence for a nuclear hormone receptor. This experiment could show whether transcriptional 
coactivator activity intrinsic to canonical PGC-1α function is occurring, If these constructs are 
functional, this would be a reasonable function to test considering the activation domain 
containing the nuclear hormone receptor binding motif (LXXLL) is retained in all of these 
constructs. An alternative approach would be immunoprecipitation of this protein followed by 
mass spectrometry, which could allow for detection of endogenous binding partners. If the 
protein is bound to PPAR or other transcription factors, we would expect endogenous 
functionality. We predicted, however, that even if the protein was capable of being translated in 
vitro, there was a chance it may have a different function from canonical PGC-1α. The 147 
amino acids of PGC-1α-b that are retained contain the activation domain only, which includes 
one LXXLL binding motif and sites which interact with SRC-1 and CBP (see Fig. 3-3C). 
Traditionally, the second LXXLL motif interacts with hormone nuclear receptors (PPARs, RXRs, 
TRs, GRs) necessary for its function as a transcriptional coactivator. It is possible that the one 
LXXLL site retained could compensate for the two missing LXXLL sites, lending it transcriptional 
coactivator function. However, it would still be missing nuclear localization signals, which may or 
may not be necessary for PGC-1α to localize to the nucleus. For example, NT-PGC-1α is 
similarly truncated compared to PGC-1α-a, and like PGC-1a-b-3T1, is missing all NLSs. Despite 
this, a small proportion of NT-PGC-1α (~10%) is localized to the nucleus and is active there 
(Zheng et al., 2009). There is no explicit reason to suggest that PGC-1α-b-3T1 would carry out 
any different functions from PGC-1α-b, because there is no new sequence to encode for 
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additional binding sites, however, there is no longer a repression domain, which could create a 
“gain of function” compared to canonical PGC-1a. This could occur since the retained activation 
domain could no longer be regulated by other proteins through the repression domain, such as 
p160 myb. This repression domain is also a region in which several post-translational 
modifications occur, which have either inhibitory or excitatory effects on PGC-1α activity (see 
Table 1-1). Since PGC-1α-b-3T1 would be missing almost all of these post-translational 
modification sites, retaining only 2 excitatory or inhibitory acetylation / deacetylation sites, it 
could change the rate of activation. Also, it is not known how many sites need to be acetylated 
or deacetylated to cause activation or inhibition of PGC-1α activity. One could argue that a 
smaller protein may be more specialized to a particular function, since only one functional 
domain would be retained. There is another possibility that this protein would only be active 
under certain conditions. This has already been evident in upregulation of PGC-1α-b transcript 
in exercised skeletal muscle and heart (Miura et al., 2008; Tadaishi et al., 2011; Thomas, R. and 
Lochmann, T., unpublished observations). Reasons for this upregulation are unknown, and also 
may not necessarily translate into changes in protein levels, as no studies have been done to 
determine whether this is the case.  Perhaps this isoform b variant would provide a redundancy 
for the role of nuclear hormone receptor transcriptional coactivator under extreme conditions 
(such as where PGC-1α-b could no longer be expressed). Since PGC-1α-b regulation is still not 
completely understood, it is difficult to presume functions for its alternatively spliced variants. 
However, identification of endogenous protein isoforms using an isoform specific antibody, in 
this case isoform b, would allow the study of functionality.  We have generated such an antibody 
using a N-terminal peptide unique to isoform b. 
By using the predicted CDS of this truncated PGC-1α-b transcript, we were able to 
create recombinant protein. This protein was created because there were no definitive positive 
controls with which to optimize our PGC-1α-b specific primary antibody, as endogenous PGC-
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1α-b protein had not yet been identified in human tissues. This construct was chosen because it 
contains CDS from a verified mature transcript in human skeletal muscle and human brain 
tissue (see Fig. 3-3B), and could thus represent a true small PGC-1α-b protein – optimal for 
verifying the quality of our antibody. 
This recombinant GST/PGC-1α-b-3T1 fusion protein was successfully expressed and 
purified from bacteria (see Fig. 3-4B). Using antibodies to both the GST and PGC-1α-b portions 
of the protein, immunoblots confirmed that the major protein species produced was in fact the 
recombinant PGC-1α-b-3T1 GST fusion protein (see fig. 3-4C-D). However, due to the series of 
lower molecular weight bands also detected by the antibodies, further support was necessary to 
determine whether these were degradation products or contaminating bacterial proteins co-
purified with our recombinant protein (see Fig. 3-4C-D).  
Upon mass spectrometry analysis to determine the identity of the bands representing 
proteins in the final elution fraction, it was determined that all bands contained GST and that 3 
out of the 4 bands visualized contained the epitope for the PGC-1α-b specific antibody (see Fig. 
3-5). This data not only allowed for optimization of the PGC-1α-b specific primary antibody to 
proceed, but it also showed that the antibody could positively detect the protein intended for 
detection (see Fig. 3-4B, D). Also, these results showed that the antibody could detect its target 
protein with some degree of specificity. This was evident because signal was detected in only 3 
out of the 4 bands visualized in the western blot utilizing this antibody; these were the same 
bands shown in mass spectrometry analysis to contain the epitope (see Fig. 3-4D, Fig. 3-5). 
The fourth band (-26 kDa), was most likely a CT degradation product in which the entirety of 
PGC-1α-b-3T1 had been cleaved from GST. This was evident in the MS results and was also 
intuitively determined prior, considering GST alone is 25 kDa. Also, anti-GST detected this band 
while the isoform b antibody did not. 
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The reasons for degradation in the GST/PGC-1α-b-3T1 fusion protein are unknown. 
Degradation appeared to have occurred during expression of the construct in bacteria, since 
lower molecular weight bands were seen prior to purification steps (see Fig. 3-4B). It was 
possible that degradation occurred upon cell lysis; however, great care was taken to include an 
excess of all protease inhibitors, with lysate treated gently and kept on ice at all times.  The 
product data sheet which came with the antibody reported that GST fusion proteins generally 
appear on stained gels with a series of lower molecular weight bands, but did not give a reason 
for this detail (Pierce, cat. #16100). Perhaps the bacteria were trying to eliminate the foreign 
protein while it was being expressed, but only partial degradation of some of the overexpressed 
product was achieved. There is also potential that translation stalled once it reached PGC-1α-b-
3T1 regions due to the bacteria’s lower abundance of correct tRNAs to produce human codons 
such as those for Leucine or Proline, which were abundant in PGC-1α-b-3T1. If this is the 
reason for degradation, codon optimization via site-directed mutagenesis could minimize this 
problem, without affecting the antigen sequence. 
Despite the degradation, the mass spectrometry data ultimately provided us with 
confirmation of the identity of our recombinant protein, GST/ PGC-1α-b-3T1 fusion, and showed 
that our antibody was able to detect PGC-1α-b protein. Western blotting conditions for the PGC-
1α-b specific antibody were then optimized. Optimized immunoblot conditions were determined 
to be a 1:100 dilution of PGC-1α-b specific primary antibody, incubated at 4°C overnight, and 
1:35,000 dilution of goat-anti-rabbit HRP-conjugated secondary antibody incubated for 1 hour at 
room temperature, both diluted in 5% nonfat dry milk in TBS-T. Using the recombinant 
GST/PGC-1α-b which was developed in order to validate this antibody, the limit of detection was 
determined to be 10 ng (see Fig. 3-6B). This antibody is the key to identifying endogenous 
PGC-1α-b isoforms, ultimately enabling us to characterize their functions. 
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Peptide competition assay of PGC-1α-b specific primary antibody enabled identification 
of putative isoform b protein variants 
After peptide-antibody incubation conditions were determined utilizing recombinant 
GST/PGC-1α-b-3T1 fusion protein (see Fig. 3-6C), several specific bands were identified in 
SY5Y WCL upon immunoblot (see Fig. 3-6D). All of the bands successfully competed by 
peptide immunogen (60-100% reduction in signal) matched the predicted size of proteins 
produced from previously identified mouse PGC-1α-b or human PGC-1α-a isoform transcripts, 
with one exception.  The isoform b specific protein which migrated at 25 kDa does not match 
well to the predicted size of any PGC-1α isoform reported. This could mean that this protein is a 
novel PGC-1α-b variant isoform, or a CT-degradation product from the larger PGC-1α-b specific 
proteins detected. 
The remaining isoform b specific proteins identified migrated at ~90, 50, 35, and 17 kDa 
(see Fig. 3-6D). The 90 kDa band most likely represents PGC-1α-b. This is the 794 aa version 
of this protein. The full transcript was identified in mice (Miura et al., 2008), however, full 
transcript has not yet been sequenced from human sources. Also, endogenous 794 aa PGC-1α-
b protein had not yet been reported in the literature, most likely because there was no way of 
differentiating between PGC-1α-a (798 aa) and PGC-1α-b (794 aa) prior to development of our 
isoform-specific antibody. Therefore, this study provides the first identification of endogenous 
PGC-1α-b protein. This is a milestone for studies of PGC-1α isoforms and would allow for in 
vitro as well as in vivo studies of verified correct full length human sequence for PGC-1α-b. I 
had begun to subclone 794 aa PGC-1α CDS into pDEST40 to use in mammalian 
overexpression experiments, but experienced difficulty in obtaining stable clones.  Since full-
length (exon 1b to exon 13) human PGC-1α-b transcript had not been fully sequenced either in 
our lab (our 5’ RACE had only revealed exon 1b – exon 5), or in published studies from other 
labs, these cloning efforts were halted until protein of the expected size could be detected. Now 
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that data supports the existence of endogenous 794 aa PGC-1α-b, cloning experiments will 
resume. The 794 aa CDS construct is also ready to clone into a lentiviral vector expressing 
fluorescent fusion protein, namely pLVX-PA-mCherry-N1 (Clontech). This way, PGC-1α-b and 
its variants can be transfected into SY5Y cells, where they have been detected, and localization 
can be determined via the fluorescent tags in immunocytochemistry experiments utilizing 
confocal microscopy. Stable clones can also be developed in order to create high, medium, and 
low level expressing PGC-1α-b isoforms. This would be optimal since highly overexpressing 
levels of PGC-1α-b may be toxic. This could be especially true in SY5Y cells since neurons 
overexpressing PGC-1α in the nigrostriatal tract became more susceptible to ROS toxicity as 
well as neurodegeneration (Ciron et al., 2012). Considering these neurons were dopaminergic 
and that SY5Y cells are dopaminergic as well, a similar effect could be observed when 
overexpressing PGC-1α-b isoforms. Therefore, having low level expressers may be essential to 
studying the effects of PGC-1α-b isoforms in cell lines. 
 The 50 kDa band most likely represents PGC-1α-2 (Ruas et al., 2012), originally 
identified as an isoform b variant present in mouse, with a predicted size of 41 kDa. In their 
PGC-1α-2 transgenic mice, however, this isoform migrated nearer to 50 kDa (Ruas et al., 2012). 
This was believed to occur due to post-translational modifications increasing the molecular 
weight. The conserved domains retained include portions of the activation and repression 
domains. The repression domain contains several sites for potential post-translational 
modifications, including acetylation by GCN5 and phosphorylation by p38 MAPK or AMPK. No 
functional studies have been conducted on this isoform to date. Due to several alternative 
splicing events differentiating PGC-1α-2 from PGC-1α-b, including the exclusion of all but 
portions of exons 3, 7, and 8 and ending in a novel exon 14, it will be interesting to see what 
functions are retained for this isoform.  
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The 35 kDa band most likely represents the isoform b version of PGC-1α-a-ex8a. PGC-
1α-a-ex8a is an isoform a variant with an alternatively spliced exon 8 (Soyal et al., 2012). This 
204 bp exon 8 includes a 9 amino acid extension from the intron between exons 7 and 8, 
resulting in the formation of an in frame stop codon, and thus a 301 aa protein. Although this 
protein is predicted to be 32 kDa, post-translational modifications could increase the molecular 
weight and therefore have a higher migration on an SDS-PAGE gel. Due to the minimal change 
in size that would occur between PGC-1α-a-ex8a and an isoform b version of this protein, the 
35 kDa band could represent a novel PGC-1α-b-ex8a. Interestingly, a 35 kDa protein of 
unknown parent transcript was identified in the mitochondrial of human brain samples as well as 
the SY5Y human neuroblastoma cell line (Choi et al., 2013). Due to similarity in size this 35 kDa 
band could represent PGC-1α-b-ex8a and thus the true identity of the mitochondrial PGC-1α 
isoform may be known. Additional experiments would be necessary in order to support this 
theory. This would include obtaining pure mitochondrial fractions from SY5Y cells and probing 
those lysates with PGC-1α-b once more. A negative control to show that this isoform is present 
only in the mitochondrion would be necessary, thus the mitochondria-extracted cytosolic fraction 
would be probed as well. If this isoform were present in the mitochondria, qRT-PCR 
experiments which observe an increase in any PGC-1α-b transcript levels upon exercise in 
mitochondrially abundant tissues (skeletal muscle, Tadaishi et al., 2012; heart, Thomas, R. and 
Lochmann, T. unpublished data) could be easily connected since an isoform b variant of PGC-
1α would be localized directly to the mitochondrion. Lastly, the 17 kDa band most likely 
represents PGC-1α-b-3T1. This isoform was identified by our lab in clones from 5’ RACE 
experiments. PGC-1α-b-3T1 encodes a 147 aa protein with a predicted molecular mass of 15.3 
kDa.  It could migrate higher on SDS-PAGE gels due to post-translational modifications. 
Acetylation via GCN5 is one such modification which can take place in the activation domain, a 
region retained in this truncated PGC-1α-b variant. Considering our lab previously identified this 
isoform and it was used to optimize our PGC-1α-b specific primary antibody, we already have 
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this construct in several different vectors, and the cDNA can be subcloned to lentiviral vectors 
very easily either from the TOPO vector or through gateway cloning (see Fig. 2-1).  
 
Since the peptide competition assay was only conducted once using SY5Y lysates, this 
experiment would need to be repeated, perhaps under conditions where 100% blocking of 
signal from specific bands could be achieved, in order to support our conclusions.100% signal 
reduction could be reached by increasing the molar excess factor by at least 40%, from 100,000 
to >140,000, determined from the percentage of no peptide control signal remaining in the 
competed sample. Also in order to provide further support for all these conclusions, I would like 
to probe SY5Y WCL side-by-side with a pan PGC-1α N-terminal antibody (EMD Millipore 
ST1202) and PGC-1α-b specific primary antibodies. This PGC-1α N-terminal antibody should 
be able to detect all b isoforms that contain part of amino acids 1-120 of canonical PGC-1α. 
Considering any predicted PGC-1α- b isoform variant would contain all but the first 12 amino 
acids of this epitope, this could serve as positive control for PGC-1α. This would show that each 
band detected as being specific for the amino acids of exon 1b also contains additional PGC-1α 
common sequence from exon 2. These blots would be complicated by the detection of isoform a 
variants as well, which could co-migrate. Alternatively, one could immunoprecipitate these 
proteins from SY5Y WCL using the PGC-1α-b specific antibody and verify their identity via 
immunoblot with the pan PGC-1α N-terminal antibody followed by mass spectrometry analysis 
(see Fig. 3-5). 
 
Creation of tools for overexpression of PGC-1α isoforms in mammalian cells for future 
functional experiments 
While PGC-1α-a and PGC-1α-b-3T1 mammalian overexpression constructs were 
created and sequence verified (see Fig. 2-1), it was found that the target CDS was able to be 
transcribed but not translated in RT-PCR experiments of transiently transfected HEK293 cells 
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(see Fig. 3-7B-C). It was not clear as to why these constructs were not being expressed. It was 
possible that the sequence was not in frame with the epitope fusion tag used to indirectly detect 
the constructs via WB. Sequencing of the exact vector aliquots used for transfection showed 
that the tags were in frame, however. Previous constructs utilizing gateway vectors displayed a 
similar phenomenon in our laboratory; removal of the vector sequence between the CMV 
promoter and the translation start lifted the block to translation. The region removed includes the 
AttB1 recombination site and the T7 promoter. Reasons as to why this may work could be that 
spacing between the promoter and the CDS may not be optimal for efficient translation. Another 
possibility is that the Kozak consensus sequence may not be strong enough to initiate 
translation. With this deletion, however, a new Kozak consensus sequence is formed, which 
may serve to enhance translation initiation. Most likely, however, the sequence between the 
CDS and the CMV promoter contains mRNA secondary structure upstream or over the 
ribosome binding site/start ATG. 
This region between the CMV promoter and CDS was deleted in the PGC-1α-b-3T1 
pDEST40 construct via site-directed mutagenesis (see Fig. 3-7C). Due to time constraints, 
transfections of these constructs were not completed prior to publication of this thesis, but will 
be conducted in the near future. Site-directed mutagenesis was attempted on the PGC-1α-a 
pDEST26 CT FLAG constructs, however, no colonies were produced which contained the 
deletion. Several different conditions were tried, including loading a range of 5-50 ng of template 
for the site-directed mutagenesis reaction, using 1-5 µL of this reaction in the transformation 
with XL1-Blue competent cells, and growing colonies at RT, 30°C, as well as 37°C. The only 
other option would be to redesign the primers used in the site-directed mutagenesis reaction. 
However, since we have recently obtained an antibody which can accurately detect endogenous 
PGC-1α (Teresa Leone, personal communication: PGC-1α-a NT aa1-120; ST1202 EMD 
Millipore), we will use this instead to detect PGC-1α-a. There is a construct used in Shock et al., 
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2011 from our lab which overexpresses PGC-1α, but does not contain a FLAG tag for 
immunodetection. Therefore, prior to the recommendation of this antibody, we were not able to 
consider using this construct in our transfections to compare to PGC-1α-b-3T1.  
It is of importance to note that all PGC-1α-a and PGC-1α-b mammalian expression 
plasmids were extremely difficult to grow in bacteria, due to the instability of the constructs. 
Growing conditions had to be altered even for the TOPO vector to grow without rearranging. 
After failure at several temperatures with TOP10 competent cells, Stbl3 cells (Invitrogen) were 
used in order to obtain stable plasmids with PGC-1α isoforms in PCR 4 TOPO (Invitrogen), 
pDONR201 (Invitrogen), and pENTR1a (Invitrogen) with growing conditions at 30°C. However, 
when glycerol stocks from the mini-prepped bacteria were used to scale up to plasmid midi-
prep, endotoxin free preparations, all clones were found to have rearranged, by DNA sequences 
analysis. Retransformation into SURE2 cells (Stratagene) prior to the gateway reaction to form 
destination vectors, with growth temperature adjusted to 37°C increased stability of these 
constructs, and no rearrangement was detected upon sequencing of the midi-preps. However, 
for unknown reasons, the distributions of fragments upon restriction digest were not as 
expected; less signal was observed from the larger fragments than the smaller ones. Although 
this is indicative of rearrangement, none was seen in sequencing. This also affected the 
apparent concentration read via nanodrop, which was much higher than the true concentration 
determined via LI-COR densitometry by a factor of 100.  After making glycerol stocks at OD 0.5 
from mini-prepped bacterial cultures and using freshly streaked colonies from these glycerol 
stocks for midi-preps, as well as only harvesting cells when OD reached between 1.0 and 1.5, I 
was able to finally obtain stable plasmid to use in transfections.     
It is also of importance to note that all PGC-1α-b human isoform variants have 2 possible 
translation start sites, ATG1 and ATG2, separated by 2 amino acids: MTHM... It is unknown 
which start site is preferred, but considering that only ATG2 is present in murine PGC-1α-b, this 
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is most likely the correct translation start site (Miura et al., 2008). Due to increased difficulty in 
obtaining stable clones for ATG1 versus ATG2 constructs, some support for ATG2 as the 
preferred translation start site is evident as well. Now that we were able to detect endogenous 
PGC-1α-b, our antibody can be used to immunoprecipitate these proteins, and Edman 
sequencing can be conducted to determine which translation start site is preferred for human 
PGC-1α-b.  
Ultimately, now that methods to produce stable clones containing these isoforms in 
various vectors exist, it should be considerably easier to create new constructs for the isoform b 
variants believed to be detected endogenously in this project for future functional studies in 
vitro. 
Perspectives 
In conclusion, this thesis was able to accomplish the goal of expanding our knowledge of 
PGC-1α and its isoforms in addition to developing necessary tools to study PGC-1α-b variants 
more extensively in the future. Epigenetics in the form of DNA methylation was found to 
correlate to the difference seen in transcript expression of PGC-1α-b versus PGC-1α-a. A novel 
isoform variant of PGC-1α-b, deemed PGC-1α-b-3T1, was identified in two different human 
tissues, and putative endogenous protein of this variant was found to be expressed in a human 
neuronal cell line. Recombinant protein of this isoform was successfully expressed, fused to 
GST for ease of purification and validation. This recombinant GST / PGC-1α-b-3T1 fusion 
protein was then used to validate our PGC-1α-b specific primary antibody, aided by mass 
spectrometry analysis and immunoblotting. This recombinant protein was also used to 
determine optimal immunoblotting conditions, limit of detection, and degree of specificity of our 
novel antibody. The antibody was then used to identify 5 putative endogenous PGC-1α-b 
isoform variant proteins in a peptide competition assay. Mammalian expression vectors 
containing PGC-1α-a and PGC-1α-b-3T1 have been developed and isoform overexpression in 
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mammalian cells will be tested using these constructs in the near future. In addition, PGC-1α-a, 
PGC-1α-b, and PGC-1α-b-3T1 are all cloned into vectors which would enable them to be moved 
easily into lentiviral vectors or fluorescently tagged vectors for siRNA knockdown and 
localization studies. Now that protocols have been optimized and tools are available to study 
these isoforms, obtaining insight into their functions is within reach.  This will allow us to gain a 
more complete picture of the varied roles of PGC-1α in mitochondrial biogenesis, metabolism, 
and disease providing the field with the required information to develop novel PGC-1α based 
therapeutics.     
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APPENDIX I 
Supplemental Figures 
	  
Fig. S1: Small scale induction for optimization of recombinant protein expression conditions.  Two 
freshly streaked colonies of PGC-1α-b-3T1 subcloned into pET41a with BamHI, XhoI (c2: part A; c3: part B) 
were chosen to look at colony-specific changes in target protein expression. Each colony was grown in 6mL 
of LB broth in a 50mL conical for 8hrs in presence of 50ug/mL Kanamycin (Kan) at 37 C with 225rpm shaking 
until OD600 reached 0.5. The cultures were then incubated at 4°C overnight. 3 mL of each culture was then 
spun down for 30s at 18K x g and resuspended in fresh LB and Kan to seed 100mL of LB + Kan. Cultures 
were grown to OD600 of 0.6, then induced with 1mM IPTG. This culture was split into 2-50mL cultures, one to 
induce for 24 hours at 18°C, and the other to induce a total of 6 hr at 37°C. 1mL aliquot timepoints were 
collected prior to induction (0 hr) as well as 2, 4, and 6 hr post induction (parts A and B) and 24 hr post 
induction for the 18°C culture only (part C). The OD600 of each of these aliquots were taken, then the cells 
were harvested at 8K rpm for 5 min, freeze thawed and lysed in 100 µL lysis buffer containing 500ug/mL 
lysozyme and benzonase with 20min rt incubation, followed by 15 min bath sonication at 4°C. Soluble fraction 
was collected after half the sample was spun for 10 min at 10K x g. Equivalent sample amounts were then 
loaded onto 7.5% acrylamide gels based on cell density (OD600). Optimal conditions (containing the most 
soluble induced target protein) were chosen as 4 hr induction at 37°C. 
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Fig. S2: Comparison of purification procedures for recombinant GST/PGC-1α-b-3T1 fusion. (A) Cultures 
were grown exactly as in Fig. S1, with the addition that 33 mL of the 100 mL culture was used to seed the 1L final 
culture volume.  Protein was induced at OD600 of 0.6 with 1mM final concentration of IPTG for 4 hr. Cells were 
then harvested at 4000 rpm for 30 min. Cell pellets were freeze thawed and lysed with lysis buffer followed by 
sonication using the large probe tip program 9, 3x. The lysate was spun for 1hr 15min at 12k x g for 1 hr, followed 
by 13.5k x g for 15 min. Soluble lysate was loaded onto Ni-NTA agarose resin, eluted in 300 mM imidazole, and 
then diluted 2 fold in equilibration buffer (same as Ni-NTA lysis buffer) in order to reduce imidazole concentration 
to a compatible 150mM for second glutathione agarose (GST) column. Protein was eluted in presence of 10 mM 
free glutathione adjusted to pH 8.0 in a total of 10mL, taken in 2 mL fractions. The first 4 lanes of part A were 
lysed as in Fig. S1.  Each lane was loaded with extract from an equivalent number of cells, based upon OD and 
resolved on a 15% acrylamide gel. s = soluble lysate fraction, t = total lysate fraction, box indicates GST / PGC-
1α-b-3T1 fusion target recombinant protein. (B) Glutathione agarose (GST) alone batch purification of 50 mL total 
culture resolved on a 4-15% gradient acrylamide gel (Bio-Rad). Cells were lysed in 2 mL total volume BugBuster 
(EMD Millipore) via 15 min bath sonication. (C) 10 ug (determined via Bradford assay) of elutions 1-3 from 
purification in part A were resolved on a 12.5% acrylamide gel. Cleaner elutions with more concentrated protein 
was obtained from purification procedure used in part B. 
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Fig.	  S3:	  	  Attempted	  detection	  of	  PGC-­‐1α-­‐a	  with	  commercially	  available	  PGC-­‐1α	  antibodies.	  The	  
expected	  size	  of	  PGC-­‐1a-­‐a	  was	  91	  kDa	  (arrow).	  HEPG2	  WCL	  was	  used	  as	  a	  positive	  control	  and	  
HEK293	  is	  the	  cell	  line	  which	  would	  be	  probed	  in	  WB	  post-­‐transient	  transfection.	  In	  each	  blot,	  each	  
lane	  contained	  50	  ug	  of	  WCL.	  (A)	  Blot	  of	  WCL	  probed	  with	  several	  concentrations	  of	  H300	  N-­‐terminal	  
PGC-­‐1α	  Ab	  (Santa	  cruz).	  Secondary	  Ab:	  GαR,	  1:5000.	  (B)	  Longer	  exposure	  of	  part	  A.	  (C)	  Blot	  of	  WCL	  
probed	  with	  several	  concentrations	  of	  K-­‐15	  Ab	  (Santa	  cruz).	  Secondary	  Ab:	  DαG,	  1:10,000.	  	  There	  was	  
no	  band	  visualized	  at	  the	  expected	  size	  of	  canonical	  PGC-­‐1α	  with	  K-­‐15	  antibody	  (Santa	  Cruz).	  A	  faint	  
band	  higher	  than	  the	  predicted	  size	  of	  canonical	  PGC-­‐1α	  was	  seen	  with	  H300,	  although	  there	  was	  
nonspecific	  binding	  observed,	  especially	  at	  75	  kDa.	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Fig. S4: Titration of purified recombinant GST/PGC-1a-b-3T1 fusion to determine PGC-1a-b specific Ab 
sensitivity. The blot contains a titration of decreasing amounts of purified recombinant GST/PGC-1α fusion 
protein. The blot was probed with a 1:16,000 dilution of PGC-1a-b specific primary Ab followed by GαR 
secondary Ab at a 1:5000 dilution. The blot was exposed with full strength dura chemiluminescent substrate 
(Thermo) for 2 s. Sensitivity at this concentration of primary was determined to be between 0.1 and 1 µg. The blot 
was exposed for up to 20 min with no change in the result shown here. 
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Fig.	  S5:	  Optimization	  of	  blocking	  conditions.	  Two	  different	  blocking	  buffers	  were	  utilized:	  T20	  
Starting	  Block	  (SB)	  (Thermo)	  and	  5%	  Nonfat	  dry	  milk	  in	  TBS-­‐T	  (NFDM).	  Pieces	  of	  PVDF	  membrane	  
containing	  no	  transferred	  samples	  were	  blocked	  for	  1	  hr	  with	  moderate	  shaking	  at	  RT.	  Membrane	  
was	  incubated	  overnight	  with	  several	  concentrations	  of	  PGC-­‐1α-­‐b	  specific	  primary	  Ab	  prepared	  in	  
the	  respective	  blocking	  buffer	  (1:100,	  1:500,	  1:1000,	  1:2000;	  only	  1:100	  shown	  here	  as	  a	  
representation).	  Membrane	  was	  then	  washed	  and	  incubated	  for	  1	  hour	  in	  several	  concentrations	  of	  
GαR	  secondary	  Ab	  (varied	  for	  each	  primary	  concentration	  used,	  based	  on	  previous	  optimization	  
experiments	  at	  those	  concentrations;	  1:30K,	  1:35K,	  1:40K,	  1:50K	  represented	  here).	  All	  combinations	  
of	  primary	  and	  secondary	  were	  each	  exposed	  in	  1/10th,	  ¼,	  ½,	  and	  full	  strength	  dura	  substrate	  for	  0s	  
(instant),	  30s,	  1min,	  and	  2min.	  The	  optimal	  blocking	  buffer	  was	  NFDM	  and	  optimal	  probing	  
conditions	  based	  on	  blot	  background	  were	  chosen	  as	  a	  1:100	  dilution	  of	  primary	  Ab	  blocked	  in	  NFDM	  
with	  1:35,000	  dilution	  of	  secondary	  Ab,	  exposed	  in	  <1/2	  dura.	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Fig. S6: Peptide competition assay optimization against WCL. Undifferentiated SH-SY5Y WCL was probed 
with pre-incubated primary antibody and a molar excess of its immunizing peptide to observe peptide competition 
and thus specificity. Molar excess factors of peptide to PGC-1α-b specific Ab of 0 (no peptide, control lane) and 
20,000 (20K lane) were used in this assay. A 1:100 dilution of primary and 1:35,000 dilution of secondary (GαR) 
in 5% NFDM TBS-T was used. Blots were exposed in 1/8 dura ECL substrate for 8s. Although 20.000 molar 
excess of peptide to antibody was enough to completely block 10 ng of recombinant protein (Fig. 5), it was not 
able to block in a WCL setting. 	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